InflammoPharmacology

, Volume 10, Issue 1–2, pp 79–155 | Cite as

Osteoarthritis IV: Clinical therapeutic trials and treatment

  • W. W. Buchanan
  • W. F. Kean

Abstract

This article discusses the potential usefulness of clinical therapeutic trials and criticises the failure of the value of guidelines in the management of osteoarthritis (OA). We have provided an overview of the benefits and side effects of non steroidal anti-inflammatory drugs (NSAIDs) in OA, including the introduction of the COX-2 selective inhibitors. In addition we have briefly reviewed the use of local NSAIDs, narcotic analgesics, injection methods, disease modifying drugs, gene therapy, surgical treatment, and non pharmacological intervention.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Abernethy, D. R., Diroll, M., Ochs, H. R., et al. (1982). Increased metabolic clearance of aceta-minophen with oral contraceptive use, Obst. Gynecol. 60, 338–341.Google Scholar
  2. Abernethy, D. R., Ameer, B. and Greenblatt, D. J. (1984). Probencid inhibition of acetaminophen and lorazepamglucuronidation, Clin. Pharmacol. Ther. 35, 224.Google Scholar
  3. Acevedo, E., Romanowicz, A., Van der Heyde, D., et al. (1999). Rofecoxib, a COX-2 specific inhibitor (C-251), had a clinical efficacy comparable to diclofenac on the treatment of knee and hip osteoarthritis (OA) in a one-year controlled trial, Ann. Rheum. Dis. (EULAR), p. 206, Abstract 858.Google Scholar
  4. Adams, M. E. (1993). An analysis of clinical studies of the use of cross-linked hyaluronan–hylan in the treatment of osteoarthritis, J. Rheumatol. 22 (Suppl. 39), 15–17.Google Scholar
  5. Adams, M. E., Atkinson, M. H., Lussier, A. J., et al. (1995). The role of viscosupplementationwith hylan G-F20 (Synvisc ® ) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial company hylan G-F20 alone, hylan G-F20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone, Osteoarthritis and Cartilage 3, 213–225.PubMedGoogle Scholar
  6. Agrawal, N., Paperiello, B., Zhao, W. W., et al. (2001). Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoidarthritis patients, Arthritis Rheum. 44 (Suppl. 9), abstract 1917, S372.Google Scholar
  7. Alarcon-Segovia, T. (1980). Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double blind comparison with aspirin and ibuprofen, J. Rheum. 6 (Suppl.), 89–99.Google Scholar
  8. Allman, R. D. and Hochberg, M. C. (1983). Degenerative joint disease, in: Clinical Trials in the Rheumatic Diseases, J. H. Klippel and J. L. Decker (Eds). W. B. Saunders, Philadelphia, Clin. Rheum. Dis. 9, 681–693.Google Scholar
  9. Altman, R. D. (1984). Review of ibuprofen for osteoarthritis, Am. J. Med. 77, 10–18.PubMedGoogle Scholar
  10. Altman, R. D. (1990). ARC Subcommittee on classification criteria of osteoarthritis: the American College of rheumatology criteria for the classification and reporting of osteoarthritis of the hand, Semin. Arthritis Rheum. 33, 1601–1610.Google Scholar
  11. Altman, R. D. (1997). The syndrome of osteoarthritis, J. Rheumatol. 24, 766–767.PubMedGoogle Scholar
  12. Altman, R. D. and Moskowitz, R. (1998). Intra-articular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial, J. Rheumatol. 25, 2203–2212.PubMedGoogle Scholar
  13. Altman, R. D., Asch, E., Blich, D., et al. (1986). Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee, Semin. Arthritis Rheum. 29, 1039–1049.Google Scholar
  14. Altman, R. D., Alarcón, G., Appelrouth, D., et al. (1991). The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip, Arthritis Rheum. 34, 505–514.PubMedGoogle Scholar
  15. Altman, R. D., Hochberg, M. C., Moskowitz, R., et al. (2000). Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatol-ogy subcommittee on osteoarthritis guidelines, Arthritis Rheum. 43, 1905–1915.PubMedGoogle Scholar
  16. Amadio, P. J. and Cummings, D. M. (1983). Evaluation of acetaminophen in the management of osteoarthritis of the knee, Curr. Ther. Res. 34, 59–66.Google Scholar
  17. Amadio, P. Jr., Cummings, D. M. and Amadio, P. (1993). Nonsteroidal anti-inflammatory drugs. Tailoring therapy to achieve results and avoid toxicity, Postgrad. Med. 93, 73–76, 79–81, 85–88.Google Scholar
  18. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. (2000). Recommen-dations for the medical management of osteoarthritis of the hip and knee. 2000 Update, Arthritis Rheum. 43, 1905–1915.Google Scholar
  19. American Pain Society Quality of Care Committee. (1995). Quality improvement guidelines for the treatment of acute pain and cancer pain, JAMA 274, 1874–1880.Google Scholar
  20. Anderson, J. J., Firschein, H. E. and Meeman, R. F. (1989). Sensitivity of a health status measure to short-termclinical changes in arthritis, Arth. Rheum. 32, 844–850.Google Scholar
  21. Andrade, L. and Fernandez, A. (1978). Sulindac in the treatment of osteoarthritis: a double-blind, 8-week study comparing sulindac with ibuprofen and 96 weeks of long-term therapy, Europ. J. Rheum. Inflamm. 1, 36–40.Google Scholar
  22. Antlitz, A. M. and Awalt, L. F. (1969). A double blind study of acetaminophen used in conjunction with oral anticoagulant therapy, Curr. Ther. Res. 11, 360–361.PubMedGoogle Scholar
  23. Antlitz, A. M., Mead, J. A. and Tolentino, M. A. (1968). Potentiation of oral anticoagulant therapy by acetaminophen, Curr. Ther. Res. 10, 501–507.PubMedGoogle Scholar
  24. Appelrouth, D. J., Baim, S., Chang, R. W., et al. (1987). Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults, Am. J. Med. 83, 78–81.Google Scholar
  25. Avila, M. H., Walker, A. M., Romieu, I., et al. (1988). Choice of non-steroidal anti-inflammatory drug in persons treated with dyspepsia, Lancet 2, 556–559.PubMedGoogle Scholar
  26. Ayral, X., Dourados, M., Listrat, V., et al. (1993). Chondroscopy: a new method for scoring chondropathy, Semin. Arthritis Rheum. 22, 289–297.PubMedGoogle Scholar
  27. Badley, E. M. (1995). The effect of osteoarthritis on disability and health care use in Canada, J. Rheumatol. 22, 19–22.Google Scholar
  28. Badley, E. M. and Wang P. P. (1998). Arthritis and the ageing population: projections of arthritis prevalence in Canada 1991 to 2031, J. Rheumatol. 25, 138–144.PubMedGoogle Scholar
  29. Badley, E. M. and Williams, J. I. (Eds). (1998). Patterns of Health Care in Ontario: Arthritis and Related Conditions: on ICES practice atlas. Toronto Institute for Clinical Evaluative Sciences, pp. 98–101.Google Scholar
  30. Balazs, E. A. and Denlinger, J. L. (1993). Viscosupplementation: a new concept in the treatment of osteoarthritis, J. Rheumatol. Suppl. 39, 3–9.Google Scholar
  31. Balazs, L., Lohmander, L. S. and Ryd, L. (1994). Intra-articular injections of hyaluronan in patients with cartilage abnormalities and knee pain. A one year double-blind, placebo-controlled study, Arthritis Rheum. 37, 521–528.PubMedGoogle Scholar
  32. Barnard-Jones, K., Davis, R. W., Lalla, O., et al. (1986). Mefenamic acid versus ibuprofen in osteoarthritis — a double-blind crossover study, Br. J. Clin. Prac. 40, 528–531.Google Scholar
  33. Bartle, W. R. and Blakely, J. A. (1991). Potentiation of warfarin anticoagulation by acetaminophen, JAMA 265, 1260.PubMedGoogle Scholar
  34. Bell, W. R. (1998). Acetaminophen and warfarin: an undesirable synergy, J. Amer. Med. Assoc. 279, 702–703.Google Scholar
  35. Bellamy, N. (1993). Musculoskeletal Clinical Metrology, Chapter 14, pp. 169–176. Kluwer Academic Publishers, Dordrecht.Google Scholar
  36. Bellamy, N. and Buchanan, W. W. (1997). Clinical evaluation in rheumatic diseases, in: Arthritis and Allied Conditions. A Textbook of Rheumatology, 13th edn, W. J. Koopman (Ed.), Vol. 1., pp. 47–79. Williams and Wilkins, Baltimore.Google Scholar
  37. Bellamy, N. and Buchanan, W. W. (2000). Clinical evaluation in the rheumatic diseases, in: Arthritis and Allied Conditons. Textbook of Rheumatology, 13th edn, W. J. Koopman (Ed.) Vol. 1, pp. 51–82. Williams and Wilkins, Baltimore, Maryland.Google Scholar
  38. Bellamy, N., Buchanan, W. W., Goldsmith, C. H., et al. (1988). Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients' osteoarthritis of the hip or knee, J. Rheumatol. 15, 1833–1840.PubMedGoogle Scholar
  39. Bellamy, N., Kirean, J., Boers, M., et al. (1997). Recommendations for a core set of outcomemeasures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III, J. Rheumatol. 24, 799–802.PubMedGoogle Scholar
  40. Bellville, J. W., Forrest, W. H., Miller, E., et al. (1971). Influence of age on pain relief fromanalgesics, J. Am. Med. Assoc. 217, 1835–1841.Google Scholar
  41. Bennett, P. and Slater, D. (1996). Cox-2 expression in labour, in: Improved Non-steroid Anti-infl ammatory Drugs. COX-2 Enzyme Inhibitors, Vane, J., Botting, J., Botting, R. (Eds), pp. 167–168. Kluwer Academic Publishers, Lancaster, and William Harvey Press, London.Google Scholar
  42. Bensen, W. G., Fiechtner, J. J., McMillen, J. I., et al. (1999). Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2inhibitor: a randomized controlled trial, Mayo. Clin. Proc. 74 (11), 1095–1105.PubMedGoogle Scholar
  43. Berkowitz, B. A., Ngai, S. H., Yang., J. C. et al. (1975). The disposition of morphine in surgical patients, Clin. Pharmacol. 17, 629–634.Google Scholar
  44. Berman, B. M., Singh, B., Lao, L., et al. (1999). A randomized trial of acupuncture as a adjunctive therapy in osteoarthritis of the knee, Rheumatology 38, 346–354.PubMedGoogle Scholar
  45. Berndt, S., Maier, C. and Schütz., H. W. (1993). Polymedication and medication compliance in patients with chronic non-malignant pain, Pain 52, 331–339.PubMedGoogle Scholar
  46. Blackshear, J. L., Napier, J. S., Davidman, M., et al. (1995). Renal complications on nonsteroidal anti-inflammatory drugs: identification and monitoring of these at risk, Sem. Arthritis Rheum. 14, 163–175.Google Scholar
  47. Boardman, P. L., Nuki, G. and Hart, F. D. (1967). Ibuprofen in the treatment of rheumatoid arthritis and osteo-arthritis, Ann. Rheum. Dis. 26, 560–561.PubMedGoogle Scholar
  48. Bolten, W. (1994). The pharmacokinetics, pharmacodynamics and comparative efficacy of flurbipro-fen, LAT, Br. J. Clin. Pract. 48, 190–195.PubMedGoogle Scholar
  49. Bombardier, C., Laine, L., Reicin, A., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. The VIGOR study group, New Engl. J. Med. 343, 1520–1528.PubMedGoogle Scholar
  50. Botting, R. (2000). Paracetamol-inhibitableCOX-2, J. Physiol. Pharmacol. 51 (4, Pt 1), 609–618.PubMedGoogle Scholar
  51. Bradley, J. D., Brandt, K. D., Katz., B. P., et al. (1991). Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee, New Engl. J. Med. 325, 87–91.PubMedGoogle Scholar
  52. Bradley, J. D., Rudy A. C., Katz, B. P., et al. (1992a). Correlationof serum concentrationsof ibuprofen sterioisomers with clinical response in the treatment of hip and knee osteoarthritis, J. Rheumatol. 19, 130–134.PubMedGoogle Scholar
  53. Bradley, J. D., Brandt, K. D., Katz, B. P., et al. (1992b). Treatment of knee osteoarthritis: Relationship of clinical features of joint inflammation to the response to a nonsteroidal anti-inflammatory drug or pure analgesic, J. Rheumatol. 19, 1950–1954.PubMedGoogle Scholar
  54. Brandt, K. D. (1993a). Should osteoarthritis be treated with nonsteroidal anti-inflammatory drugs?, Rheum. Dis. Clin. North Amer. 19, 29–44.Google Scholar
  55. Brandt, K. D. (1993b). Should non-steroidal anti-inflammatory drugs be used to treat osteoarthritis?, Rheum. Dis. Clin. North Amer. 19, 697–712.Google Scholar
  56. Brandt, K. D. (1993c). NSAIDs in the treatment of osteoarthritis. Friends or foes?, Bull. Rheum. Dis. 42, 1–4.Google Scholar
  57. Brandt, K. D. (2001). A critique of the 2000 update of the American College of Rheumatology recommendationsfor management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2451–2455.PubMedGoogle Scholar
  58. Brandt, K. D. and Palmoski, M. J. (1984). The effects of salicylates and other nonsteroidal anti-infl ammatory drugs on articular cartilage, Am. J. Med. 77, 65–69.Google Scholar
  59. Brandt, K. D. and Schumacher, H. R. Jr. (1995). Osteoarthritis and crystal deposition diseases, Curr. Opin. Rheumatol. 7, 343–345.Google Scholar
  60. Breder, C. D., Dewitt, D. and Kraig, R. P. (1995). Characterizationof inducible cyclooxygenase in rat brain, J. Comp. Neurol. 355, 296–315.PubMedGoogle Scholar
  61. Bresnihan, B., Hughes, G. and Essigman, W. K. (1978). Diflunisal in the treatment of osteoarthritis: a double-blind study comparing diflunisal with ibuprofen, Curr. Med. Res. Opin. 5, 556–561.PubMedGoogle Scholar
  62. Brideau, C., Kargmans, S., Liu, S., et al. (1996). A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitor, Inflamm. Res. 45, 68–74.PubMedGoogle Scholar
  63. Brodie, N. H., McGhie, R. L., O'Hara, H., et al. (1980). Fenclofenac and ibuprofen in the treatment of osteoarthritis, Br. J. Clin. Prac. 34, 334–336.Google Scholar
  64. Brooke, J. W. (1976). Fenoprofen therapy in large joint osteoarthritis: double-blind comparison with aspirin and long-term experience, J. Rheum. 3 (Suppl), 71–75.Google Scholar
  65. Brooks, P. M. and Buchanan, W. W. (1991). Predication of the clinical efficacy of and intolerance to anti rheumatic drug therapy, in: Prognosis in the Rheumatic Diseases, N. Bellamy (Ed.), pp. 347–402. Kluwer Academic Publishers, Lancaster, England.Google Scholar
  66. Brooks, P. M. and Day, R. O. (1991). Non-steroidal anti-inflammatory drugs: differences and similarities, New Engl. J. Med. 324, 1716–1725.PubMedGoogle Scholar
  67. Brooks, P. M., Dougan, M. A., Mugford, A., et al. (1982). Comparative effectivenessof five analgesics in patients with rheumatoid arthritis and osteoarthritis, J. Rheumatol. 9, 732–736.Google Scholar
  68. Brooks, P., Emery, P., Evans, J. F., et al. (1999). Interpretingthe clinical significance of the differential inhibition of cyclooxygenase-1and cyclooxygenase-2, Rheum. 38, 779–788.Google Scholar
  69. Buchanan, W. W. and Bellamy, N. (1992). The controlled clinical trial: the gold standard with clay feet, in: Rheumatology: State of the Art, G. Balint, B. Yomov, L. Hodinka (Eds), pp. 229–301. Excerpta Medica, Amsterdam.Google Scholar
  70. Buchanan, W. W. and Brooks, P. M. (1991). Prediction of organ system toxicity with anti rheumatic drug therapy, in: Prognosis in the Rheumatic Diseases, N. Bellamy (Ed.), pp. 403–450. Kluwer Academic Publishers, Lancaster, England.Google Scholar
  71. Buchanan, W. W. and Kean, W. F. (1987). Current nonsteroidal anti-inflammatory drug therapy in rheumatoid arthritis, with an emphasis in the elderly, Nonsteroidal Anti-inflammatory DrugsDe s, Chap. 2, pp. 9–29. Marcel Dekker, New York.Google Scholar
  72. Buchanan, W. W. and Kean, W. F. (2001). Evidence based medicine: the median is not the message, J. Rheumatol. 28, 2371–2372.PubMedGoogle Scholar
  73. Buchanan, W. W. and Kean, W. F. (2002). OA II: Pathology and pathogenesis, Inflammopharmacology 10, 23–52.Google Scholar
  74. Buckland-Wright, J. C. (1994). Quantitative radiography of osteoarthritis, Ann. Rheum. Dis. 53, 268–275.PubMedGoogle Scholar
  75. Buckland-Wright, J. C., McFarlane, D. G., Lynch, J. A., et al. (1995a). Joint space width measures cartilage thickness in osteoarthritis of the knee: high resolution plain film and double contrast macroradiographic investigation, Ann. Rheum. Dis. 54, 263–268.PubMedGoogle Scholar
  76. Buckland-Wright, J. C., McFarlane, D. G., Lynch, J. A., et al. (1995b). Quantitative microfocal radiography detects changes in OA knee joint space width in patients in placebo controlled trial of NSAID therapy, J. Rheumatol. 22, 937–943.PubMedGoogle Scholar
  77. Buckwalter, K. A. (1993). Imaging in OA and crystal deposition diseases, Curr. Opin. Rheumatol. 5, 503–509.PubMedGoogle Scholar
  78. Bueijinga, J. J., Boerstra, E. E., Ris, P., et al. (1982). Interaction between paracetamol and coumadin anticoagulants, Lancet 1, 506.Google Scholar
  79. Bunting, S., Moncada, S. and Vane, J. R. (1983). The prostacyclin–thromboxane balance: pathophys-iological and therapeutic considerations, Br. Med. Bull. 39, 271–276.PubMedGoogle Scholar
  80. Bunyaratavej, N., Keorochana, S. and Pithkul, S. (2001). Sefety and efficacy of meloxicam 7.5 mg in the treatment of osteoarthritis in Thai patients, J. Med. Assoc. Thai. 84, s542–546.PubMedGoogle Scholar
  81. Busson, M. (1986). Update on ibuprofen: review article, J. Int. Med. Res. 14, 53–62.PubMedGoogle Scholar
  82. Caldwell, J. R., Crain, D., Hoffmeister, R. T., et al. (1983). Four-way multicentre, crossover trial of ibuprofen, fenoprofen calcium, naproxen and tolmetin sodium in osteoarthritis: comparative clinical profiles, Southern. Med. J. 76, 706–711.Google Scholar
  83. Caldwell, J. R., Hale, M. E., Boyd, R. E., et al. (1999). Treatment of osteoarthritis pain with con-trolled release oxycodone or fixed combination oxycodone plus acetaminophen added to non-steroidal anti-inflammatory drugs: a double-blind, randomized, multicenter, placebo-controlled trial, J. Rheumatol. 26, 862–869.PubMedGoogle Scholar
  84. Callahan, C. M., Drake, B. G., Heck, D. A., et al. (1994). Patient outcomes following tricompartmen-tal total knee replacement. A meta-analysis, J. Am. Med. Assoc. 271, 1349–1357.Google Scholar
  85. Candy, J. M., Morrison, C., Paton, R. D., et al. (1998). Salicylate toxicity masquerading as malignant hypertension, Paediatric Anaesthesia 8, 421–423.PubMedGoogle Scholar
  86. Cannon, G., Caldwell, J., Holt, P., et al. (1998). MK-0966, a specific COX-2 inhibitor, for clinical efficacy comparable to Diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26 week controlled clinical trial, Arthitis Rheum. 41 (Suppl. 9), S83.Google Scholar
  87. Cannon, G. W., Caldwell, J., Holt P., et al. (2000). Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip, Arthritis Rheum. 43, 978–987.PubMedGoogle Scholar
  88. Capell, H. A., Rennie, J. A. N., Rooney, P. J., et al. (1979). Patient compliance: a novel method of testing nonsteroidal anti-inflammatory analgesics in rheumatoid arthritis, J. Rheumatol. 6, 584–593.PubMedGoogle Scholar
  89. Care, G. R., Harfield, B. and Chamberlain, M. A. (1981). And have you done your exercises?, Physiotherapy. 67, 180.PubMedGoogle Scholar
  90. Caron, J. P., Fernandes, J. C., Martel-Pelletier, J., et al. (1996). Chondroprotective effect of intraar-ticular injection of interleukin-1 receptro antagonist in experimental osteoarthritis: suppression of collagenase-1 expression, Arthritis Rheum. 39, 1535–1544.PubMedGoogle Scholar
  91. Carr, A J. (1999). Beyond disability: measuring the social and personal consequences of osteoarthritis, Osteoarthritis Cartilage 7, 230–238.PubMedGoogle Scholar
  92. Catella-Lawson, F., McAdam, B., Morrison, B. et al. (1999). Effects of specific inhibitor of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids, J. Pharm. Exper. Ther. 289, 735–741.Google Scholar
  93. Chahade, W. H. and Josef, H. (1978). Clinical evaluation of the efficacy and tolerance of sulindac in patients with osteoarthritis of the hip and/ or knee during 144 weeks: Comparative study with aspirin during the first 96 weeks, Eur. J. Rheum. Inflam. 1, 41–44.Google Scholar
  94. Chakraborty, I., Das, S. K., Wang, J., et al. (1996). Developmental expression of the cyclooxygenase-1 and cyclooxygenase-2genes in the peri-implantationmouse uterus and their differential regulation by the blastocyst and ovarian steroids, J. Mol. Endocrinol. 16, 107–122.PubMedGoogle Scholar
  95. Chamberlain, M. A., Care, G. and Harfield, B. (1982). Physiotherapy in osteoarthritis of the knees. A controlled trial of hospital versus home exercises, Int. Rehab. Med. 4, 101–106.Google Scholar
  96. Chan, T. Y. (1990). Potential dangers from topical preparations containing methylsalicylate, Human and Exper. Toxicol. 15, 747–750.Google Scholar
  97. Chen, M. M. and Lee, C. S. (1985). Cimetidine–acetaminophen interaction in humans, J. Clin. Pharmacol. 25, 227–229.PubMedGoogle Scholar
  98. Chrubasik, S., Eisenberg, E., Balan, E., et al. (2000). Treatment of low back pain exacerbations with willow bark extract: a randomized double-blind study, Am. J. Med. 109 (1), 9–14.PubMedGoogle Scholar
  99. Cimmino, M. A., Cutolo, M., Samanta, E., et al. (1982). Short-term treatment of osteoarthritis: a comparison of sodium meclofenamate and ibuprofen, J. Int. Med. Res. 10, 46–52.PubMedGoogle Scholar
  100. Clive, D. M. and Stoff, J. S. (1984). Renal syndromes associated with nonsteroidal anti-inflammatory drugs, New Engl. J. Med. 310, 563–572.PubMedGoogle Scholar
  101. Cockcroft, D. W. and Gault, M. H. (1976). Prediction of creatinine clearance from serum creatinine, Nephron. 16, 31–41.PubMedGoogle Scholar
  102. Cohen-Haguenauer, O. (1995). Overview of regulation of gene therapy in Europe: a current statement including reference to US regulation, Hum. Gene. Ther. 6, 773–785.PubMedGoogle Scholar
  103. Cooper, D. E. and DeLee, J. C. (1994). Reflex sympathetic dystrophyof the knee, J. Am. Acad. Orthop. Surg. 2, 79–86.PubMedGoogle Scholar
  104. Cooper, S. A. (1984). Five studies on ibuprofen for postsurgical dental pain, Am. J. Med. 77, 70–77.PubMedGoogle Scholar
  105. Cooper, S. A., Schachtel, B. P., Goldman, E., et al. (1989). Ibuprofen and acetaminophen in the relief of acute pain: A randomised double-blind, placebo-controlled study, J. Clin. Pharmacol. 29, 1026–1030.PubMedGoogle Scholar
  106. Co-Operating Clinics Committee. (1973). A controlled trial of gold salt therapy in rheumatoid arthritis, Arthritis Rheum. 16, 353–358.Google Scholar
  107. Cornhill, J. and Rowley-Jones, D. (1984). Is sustained release ibuprofen as effective as piroxicam? A comparison in patients with osteoarthritis, Eur. J. Rheum. Inflam. 7, 114–121.Google Scholar
  108. Creamer, P. (2000). Osteoarthritis pain and its treatment, Curr. Opin. Rheumatol. 12, 450–455.PubMedGoogle Scholar
  109. Creamer, P. and Hochberg, M. C. (1997). Why does osteoarthritis of the knee hurt? —sometimes, Br. J. Rheumatol. 36, 726–728.PubMedGoogle Scholar
  110. Creamer, P. and Hochberg, M. C. (1998). The relationship between psychological variables and pain reporting in osteoarthritis of knee, Arthritis Care Res. 11, 60–65.PubMedGoogle Scholar
  111. Creamer, P., Hunt, M. and Dieppe, P. (1996). Pain mechanisms in osteoarthritis of the knee: effect of intra-articular anaesthetic, J. Rheumatol. 23, 1031–1036.PubMedGoogle Scholar
  112. Creamer, P. and Lethbridge-Cejku, M. and Hochberg, M. C. (1998). Where does it hurt? Pain localization in osteoarthritis of the knee, Osteoarthritis Cartilage 6, 318–323.PubMedGoogle Scholar
  113. Creamer, P., Lethbridge-Cejku, M., Costa, P., et al. (1999a). The relationship of anxiety and depression with self-reported knee pain in the community: Data from the Baltimore Longitudinal Study of Aging, Arthritis Care Res. 12, 3–7.PubMedGoogle Scholar
  114. Creamer, P., Lethbridge-Cejku, M. and Hochberg, M. C. (1999b). Determinants of pain severity in knee osteoarthritis: effect of demographic and psychosocial variables using 3 pain measures, J. Rheumatol. 26, 1785–1792.PubMedGoogle Scholar
  115. Crippen, J. S. (1993). Acetaminophen hepatotoxicity: Potentiation by isoniazid, Am. J. Gastroenterol. 88, 590–592.PubMedGoogle Scholar
  116. Crofford, L. J. (1997). COX-1 and-2 tissue expression; implications and prediction, J. Rheumatol. 24 (Suppl. 49), 15–19.Google Scholar
  117. Crofford, L. J., Wilder, R. L., Ristimaki, A. P., et al. (1994). Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues: effects of interleukin-1ß, phorphol ester, and corticosteroids, J. Clin. Invest. 93, 1095–1101.PubMedGoogle Scholar
  118. Crome, P., Kimber, G. R., Wainscott, G., et al. (1981). The effect of the simultaneous administration of oral metoclopramide on the absorption of paracetamol in healthy volunteers, Br. J. Clin. Pharmacol. 11, 430–431P.Google Scholar
  119. Crowther, R., Holbrook, A. M., Kenwright, R., et al. (1997). Drug interactions among commonly used medications. Chart simplifies data from critical literature review, Canad. Family Physician 43, 1972–1981.Google Scholar
  120. Cryer, B. and Feldman, M. (1998). Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs, Am. J. Med. 104, 413–421.PubMedGoogle Scholar
  121. Dahlberg, L., Lohmander, L. S. and Ryd, L. (1994). Intra articular injections of hyaluronanin patients with cartilage abnormalities and knee pain. A one year double-blind, placebo-controlled study, Arthritis Rheum. 37, 521–528.PubMedGoogle Scholar
  122. Dart, R. C. and Kuffner, E. K. (2001). Use of acetaminophen in alcoholic patients: comment on the 2000 update of the American College of Rheumatology recommendations for management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2449.Google Scholar
  123. Davenport H. W. (1967). Salicylate damage to the gastric mucosal barrier, N. Engl. J. Med. 276, 1307–1312.PubMedGoogle Scholar
  124. Davies, G. M., Watson, D. J. and Bellamy, N. (1999). Comparison of the responsiveness and relative effect size of the Western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized clinical trial of osteoarthritis patients, Arthritis Care Res. 12, 172–179.PubMedGoogle Scholar
  125. Davis, M. A., Ettinger, W. H., Neuhaus, J. M., et al. (1992). Correlates of knee pain among US adults with and without radiographic knee osteoarthritis, J. Rheumatol. 19, 1943–1949.PubMedGoogle Scholar
  126. Day, R., Luza, A., Castenada, O., et al. (1999). Rofecoxib, a COX-2 specific inhibitor (C-251), had clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trail, Ann. Rheum. Dis. (EULAR) p. 207, Abstract 860.Google Scholar
  127. de Blécourt, J. J. (1975a). A comparative study of ibuprofen (Brufen) and indomethacin (Indocid) in uncomplicated gonarthrosis and coxarthrosis, Curr. Med. Res. and Opin. 3, 477–480.Google Scholar
  128. de Blécourt, J. J. (1975b). A comparative study of ibuprofen (Brufen) and indomethacin (Indocid) in uncomplicated arthrosis, Nederlands tijdschrift voor Geneeskund, 119 (Suppl. 51), 2032–2034.Google Scholar
  129. de Brum-Fernandez, A. J. (1997). New perspectives for non-steroidal anti-inflammatory therapy, J. Rheumatol. 24 (2), 246–248.PubMedGoogle Scholar
  130. de Meijer, A. Vollard, H., de Metz, M., et al. (1999). Meloxicam, 15 mg/ day, spares platelet function in healthy volunteers, Clin. Pharmacol. Ther. 66, 425–430.PubMedGoogle Scholar
  131. Deal, C. L. and Moskowitz, R. W. (1999). Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate, Rheum. Clinics N. Amer. 25, 279–295.Google Scholar
  132. Deal, C. L., Schnitzer, T. J., Lipstein, E., et al. (1991). Treatment of arthritis with topical capsaicin: a double-blind trial, Clin. Therapeutics 13, 383–395.Google Scholar
  133. Deener, F. and Richardson, B. (2001). Review of gastrointestinal tolerability and safety of Meloxicam, Inflammopharm. 9, 71–80.Google Scholar
  134. Degner, F. and Richardson, B. (2001). Review of gastrointestinaltolerability and safety of Meloxicam, Inflammopharmacology 9, 71–80.Google Scholar
  135. Dequeker, J., Hawkey, C., Kahan, H., et al. (1998). Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis, Brit. J. Rheumatol. 37, 946–951.Google Scholar
  136. Deyle, G. D., Henderson, N. E., Matekel, R. L., et al. (1999). Effectiveness of manual physical therapy and exercise of the knee, Am. Intern. Med. 132, 173–181.Google Scholar
  137. Di Perri, T., Auteri, A., Caruso, I., et al. (1987b). Multi-center double-blind randomized clinical trial of imidazole salicylate versus ibuprofen in patients with osteoarthritis, Int. J. Clin. Pharm. Ther. Tox. 25, 479–482.Google Scholar
  138. Diamond, H. S. (1976). Double-blind crossover study of fenoprofen and aspirin in osteoarthritis, J. Rheum. 3 (Suppl), 67–70.Google Scholar
  139. Dick, C., Dick, P. H., Nuki, G., et al. (1969). Effects of anti-inflammatory drug therapy on clearance of 133 Xe from knee joints in patients with rheumatoid arthritis, Br. Med. J. 3, 278–280.PubMedGoogle Scholar
  140. Dieppe, P. (1993). Management of osteoarthritis of the hip and knee joints, Curr. Opin. Rheumatol. 5, 487–493.PubMedGoogle Scholar
  141. Dieppe, P. (2001). Concerns about the methodology used in developing the 2000 update of the Amer-ican College of Rheumatology recommendations for management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2450–2451.PubMedGoogle Scholar
  142. Dieppe, P. A. and Huskisson, E. C. (1978). Diflunisal and acetylsalicylic acid: a comparison of efficacy in osteoarthritis, of nephrotoxicity, and of anti-inflammatory activity in the rat, in: Diflunisal in Clinical Practice, Proceedings of a Conference at the XIVth International Congress of Rheumatology, San Francisco, K. Miehlke, (Ed.), pp. 57–61. Futura, New York.Google Scholar
  143. Dieppe, P. and Huskinsson, E. (1979). Diflusinal and aspirin: a comparison of efficacy and nephrotoxicityin osteoarthritis, Rheumatol. Rehabil. 18, 53–56.PubMedGoogle Scholar
  144. Dieppe, P. A., Sathapatayavongs, B., Jones, H. E., et al. (1980). Intra-articular steroids in osteoarthri-tis, Rheumatol. Rehab. 19, 212–217.Google Scholar
  145. Dieppe, P., Cushnaghan, J., Jasani, M. K., et al. (1993a). A two year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint, B. J. Rheumatol. 32, 595–600.Google Scholar
  146. Dieppe, P., Cushnaghan, J., Young, P., et al. (1993b). Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy, Ann. Rheum. Dis. 52, 557–563.PubMedGoogle Scholar
  147. Dieppe, P. A., Franke., S. J. and Toth, B. (1993c). Is research into treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected?, Lancet 341, 353–354.PubMedGoogle Scholar
  148. Dieppe, P., Basler, H. D., Chard, J., et al. (1999). Knee replacement surgery for osteoarthritis: effec-tiveness, practice variations, indications and possible determinants of utilization, Rheumatology 38, 73–83.PubMedGoogle Scholar
  149. Dieppe, P., Cushnaghan, J., Tucker, M., et al. (2000). The Bristol OA 500 study: progression and impact of the disease after 8 years, Osteoarthritis Cartilage 8, 63–68.PubMedGoogle Scholar
  150. DiPasquale, G. (1993). Pharmacologic control of cartilage degeneration in osteoarthritis, in: Joint Cartilage Degeneration: Basic and Clinical Aspects, J. F. Woessner, D. S. Howell (Eds), pp. 457–502. Marcel Dekker, New York.Google Scholar
  151. Dixon, A. S., Jacoby, R. K. and Berry, H. (1988). Clinical trial of intra-articular injection of sodium hyaluronate in patients with osteoarthritis of the knee, Curr. Med. Res. Opin. 11, 205–213.PubMedGoogle Scholar
  152. Doherty, M. and Jones, A. (1995). Indomethacin hastens large joint osteoarthritis in humans — how strong is the evidence?, J. Rheumatol. 22, 2013.PubMedGoogle Scholar
  153. Dordoni, B., Willson, R. P. H., Thompson, R. P. H., et al. (1973). Reduced absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure, Br. Med. J. 3, 86–87.PubMedGoogle Scholar
  154. Downie, R. S. and Macnaughton, J. (2000). Clinical Judgement. Evidence in Practice. Oxford University Press, Oxford, England.Google Scholar
  155. Doyle, D. V., Dieppe, P. A., Scott, J., et al. (1981). An articular index for the assessment of osteoarthritis, Ann. Rheum. Dis. 40, 75–78.PubMedGoogle Scholar
  156. Dreiser, R. L. and Tisne-Camus, M. (1993). DHEP plasters as a topical treatment of knee OA — a double-blind placebo-controlled study, Drugs under Experimental and Clinical Research 19, 117–123.PubMedGoogle Scholar
  157. Dunn, M. J. (1987). The role of arachidonic acid metabolites in renal homeostasis: nonsteroidal anti-infl ammatory drugs on renal function and biochemical, histological and clinical effects and drug interactions, Drugs 33 (Suppl. 1), 56–66.PubMedGoogle Scholar
  158. Dunn, M. J. and Zambraski, E. J. (1980). Renal effects of drugs that inhibit prostaglandin synthesis, Kidney Int. 18, 609–622.PubMedGoogle Scholar
  159. Easterbrook, P. J., Berlin, J. A., Gopalan, R., et al. (1991). Publicationbias in clinical research, Lancet 337, 867–872.PubMedGoogle Scholar
  160. Eccles, M., Freemantle, N., Mason, J., et al.(1998). North of England Nonsteroidal Anti-inflammatory Drug Guideline Group. North of England Evidence-based Guideline Development Project: sum-mary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis, Brit. Med. J. 317, 526–530.PubMedGoogle Scholar
  161. Editorial (1999). Osteoarthritis: time to shift to paradigm, Brit. Med. J. 318, 1299–1300.Google Scholar
  162. Edwards, R. and Oliphant, J. (1992). Paracetamol toxicity in chronic alcohol abusers — a plea for greater consumer awareness, NZ Med. J. 105, 174–175.Google Scholar
  163. Egger, M. and Davey-Smith, G. (1995). Misleading meta-analysis, Br. Med. J. 310, 752–754.Google Scholar
  164. Ehrich, E., Schnitzer, T., Kivitz, A., et al. (1997). MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee, and hip in a 6-week placebo controlled study, Arth. Rheum. 40 (Suppl. 9), S85.Google Scholar
  165. Ehrich, E., Bolognese, J., Kong, S., et al. (1998a). Improvement in SF 36 mental health domains with treatment of OA: result of decreased pain and disability or independent mechanisms, Arth. Rheum. 41 (Suppl. 9), 1134.Google Scholar
  166. Ehrich, E., Schnitzer, T., Weaver, A., et al. (1998b). Treatment with MK-966 (Vioxx™), a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis of the knee and hip that was sustained over six months, Rheum. in Europe 27 (Suppl. 2).Google Scholar
  167. Ekstrom, P., Carling, L., Wetterhus, S., et al. (1996). Prevention of peptic ulcer and dyspeptic symptoms with omeprozole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study, Scand. J. Gastroenterol. 31, 753–758.PubMedGoogle Scholar
  168. Elliott, S. L., Yeomand, N. D., Buchanan, R. R., (1994). Efficacy of 12 months misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial, Scand. J. Rheumatol. 23, 171–176.PubMedGoogle Scholar
  169. Emery, P. (1996). Pharmacology safety and therapeutics of COX-2 inhibitors, in: Improved Non-Steroidal Anti-Inflammatory Drugs, Vane, J., Botting, J. and Botting, R. (Eds), pp. 229–242. Kluwer, Dordrecht, The Netherlands.Google Scholar
  170. Essigman, W. K., Chamberlain, M. A. and Wright, V. (1979). Diflunisal in osteoarthrosis of the hip and knee, Ann. Rheum. Dis. 38, 148–151.PubMedGoogle Scholar
  171. Ettinger, W. H. J. and Afable, R. F. (1994). Physical disability from knee osteoarthritis: the role of exercise as an intervention, Med. Sci. in Sports and Exercise 26, 1435–1440.Google Scholar
  172. Ettinger, W. H. Jr., Burns, R., Messier, S. P., et al. (1997). A randomized trial comparing aerobic exercise and resistance exercise with a health education program in older adults with knee osteoarthritis. The Fitness Arthritis and Seniors Trial (FAST), J. Am. Med. Assoc. 277, 25–31.Google Scholar
  173. European Drug Guidelines. (1985). Guidelines for the Clinical Investigators of Drugs used in Rheumatic Diseases. European Drug Guidelines, Series 5. World Health Organization. Regional Office for Europe, Copenhagen. European League against Rheumatism. March, pp. 21–24.Google Scholar
  174. Evans, C. H. and Robbins, P. D. (1994). Gene therapy for arthritis, in: Gene Therapeutics: Methods and applications of direct gene transfer, Wolff, J. A. (Ed.), pp. 320–324. Birkhauser, Boston.Google Scholar
  175. F.D.A. Guidelines (1988). Guidelines for the Clinical Evaluation of Anti-rheumatic Drugs (Adult and Children). U.S. Department of Health and Human Services. Public Health Services. Food and Drug Administration, April, 115.Google Scholar
  176. Felson, D. T. (2001). The verdict favors nonsteroidal antiinflammatory drugs for treatment of osteoarthritis and a plea for more evidence on other treatments, Arthritis Rheum. 44, 1477–1480.PubMedGoogle Scholar
  177. Felson, D. T., Zhang, Y., Hannan, M. T., et al. (1997). Risk factors for incident radiographic knee osteoarthritis in the elderly: the FraminghamStudy, Arthritis Rheum. 40, 728–733.PubMedGoogle Scholar
  178. Fernandes, J., Tardif, G., Martel-Pelletier, J., et al. (1999). In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints. Prevention of osteoarthritis progression, Am. J. Pathol. 154, 1159–1169.PubMedGoogle Scholar
  179. Fernandes, J. C., Martel-Pelletier, J. and Pelletier, J. P. (2000). Gene therapy for osteoarthritis — new perspectives for the twenty-first century, Clin. Orthop. Rel. Res. 379 (Suppl.), 262–272.Google Scholar
  180. Ferreira, S. H. (1980). Peripheral analgesia: mechanism of the analgesic action of aspirin like drugs and opiate-antagonists, Br. J. Clin. Pharmacol. 10, 237S–245S.PubMedGoogle Scholar
  181. Fisher, C. A., Curtis, S. P., Resnick, H., et al. (2001). Treatment with etoricoxib, a cox-2 selective inhibitor, resulted in clinical improvement in knee and hip osteoarthritis (OA) over 52 weeks, Arthitis Rheum. 44 (Suppl. 9), abstract 495, S135.Google Scholar
  182. Fisher, N. M., Pendergast, D. R., Gresham, G. E., et al. (1991). Muscle rehabilitation: its effect on muscular and functional performance of patients with knee osteoarthritis, Arch. Phys. Med. Rehabil. 72, 367–374.PubMedGoogle Scholar
  183. Fisher, N. M., Gresham, G. E., Abrams, M., et al. (1993). Quantitative effects of physical therapy on muscular and functional performance in subjects with osteoarthritis of the knees, Arch. Phys. Med. Rehabil. 74, 840–847.PubMedGoogle Scholar
  184. Fitzmaurice, D. A. and Murray, J. A. (1997). Potentiationof anticoagulant effect of warfarin, Postgrad. Med. J. 73, 439–440.PubMedGoogle Scholar
  185. Floren, C.-H., Thesleff, P. and Milsson, A. (1987). Severe liver damage caused by therapeutic doses of acetaminophen, Acta. Med. Scand. 222, 285–288.PubMedGoogle Scholar
  186. Foldes, K., Brandt, P., Gaal, M., et al. (1992). Nocturnal pain correlates with effusions in diseased hips, J. Rheumatol. 19, 1756–1758.PubMedGoogle Scholar
  187. Forrest J. B. (1992). Sympathetic mechanisms of acute pain, Can. J. Anaesth. 39, 523–527.PubMedGoogle Scholar
  188. Forrest J. B. (1998). Pathophysiology of acute pain, in: Acute Pain: Pathophysiology and Treatment, Forrest, J. (Ed.), pp. 31–65. Manticore, Grimsby Ontario, Canada.Google Scholar
  189. Fortin, P. R., Clarke, A. E., Joseph, L., et al. (1999). Outcomes of total hip and knee replacement: preoperative functional status predicts outcomes at six months after surgery, Arthritis Rheum. 42, 1722–1728.PubMedGoogle Scholar
  190. Fox P. L., Raina P. and Jadad A. R. (1999). Prevalence and treatment of pain in older adults in nursing homes and other long-termcare institutions: a systematic review, Can. Med. J. 160, 329–333.Google Scholar
  191. Fremont-Smith, P. and Bayles, T. B. (1965). Salicylate therapy in rheumatoid arthritis, JAMA 192, 113–116.Google Scholar
  192. Friedman, D. M. and Moore, M. E. (1980). The efficacy of intra articular steroids in osteoarthritis: a double-blind study, J. Rheumatol. 7, 850–856.PubMedGoogle Scholar
  193. Fries, J. F., Spitz, P., Kraines, G. R., et al. (1980). Measurement of patient outcome in arthritis, Arthritis Rheum. 23, 137–145.PubMedGoogle Scholar
  194. Fries, J. F., Williams, C. A. and Bloch D. A. (1991). The relative toxicity of nonsteroidal antiinflam-matory drugs, Arthritis Rheum. 34, 1353–1360.PubMedGoogle Scholar
  195. Fröhlich, J. C. (1995). Prostaglandin ecdoperoxidase synthetase isoenzymes. The clinical relevance of selective inhibition, Ann. Rheum. Dis. 54, 942–943.PubMedGoogle Scholar
  196. Gaffney, K., Ledingham, J. and Perry, J. D. (1995). Intra-articulartriamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response, Ann. Rheum. Dis. 54, 379–381.PubMedGoogle Scholar
  197. Garcia-Rodriguez, L. A., Cattaruzzi, C., et al. (1998). Risk of hospitalizationfor upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs, Arch. Intern. Med. 158, 33–39.PubMedGoogle Scholar
  198. Garcia-Rodriguez, L. A. and Hernadez-Diaz S. (2001). Relative risk of upper gastrointestinal compli-cations among users of acetaminophen and non-steroidal anti-inflammatory drugs, Epidemiol. 12, 570–576.Google Scholar
  199. Gerecz-Simon, E. and Kean, W. F. (1999a). Methods for application of topical nonsteroidal anti-infl ammatory drugs (TNSAIDs) in clinical trials, Inflammopharmacology 7, 329.Google Scholar
  200. Gerecz-Simon, E. and Kean, W. F. (1999b). Efficacy and safety of topical nonsteroidal anti-inflammatory drugs (TNSAIDs) in musculoskeletal disorders, Inflammopharmacology 7, 330–331.Google Scholar
  201. Ghosh, P. (1988). Anti-rheumatic drugs and cartilage, Baillière's Clin. Rheumatol. 2, 309–338.Google Scholar
  202. Ghosh, P., Wells, C., Smith, M., et al. (1990). Chondroprotection, myth or reality: an experimental approach, Semin. Arthritis Rheum. 19 (Suppl. 1), 3–9.PubMedGoogle Scholar
  203. Gibb, W. and Sun, M. (1996). Localization of prostaglandin H synthase type 2 protein and mRNA in term human fetal membranes and decidua, J. Endocrinol. 150, 497–503.PubMedGoogle Scholar
  204. Glorioso, S., Todesco, S., Mazzi, A., et al. (1985). Double-blind multicentre study of the activity of S-adenosylmethioninein hip and knee osteoarthritis, Int. J. Clin. Pharm. Res. 5, 39–49.Google Scholar
  205. Goodman, M. J., Kent, P. W. and Truelove, S. C. (1986). Inhibition of glucosamine synthesis by salicylates hydrocortisone and two non-ulcerogenic drugs, Arch. Int. Pharmacodyn. Ther. 226, 4–10.Google Scholar
  206. Gould, G. S. (1996). Death and horses: two cases for the primacy of variation, in: Full House, The Spread of Excellence from Plato to Darwin, pp. 43–73. Harmony Books, New York.Google Scholar
  207. Grace, D., Rogers. J., Skeith, K., et al. (1999). Topical diclofenac versus placebo: a double blind randomized clinical trial in patients with osteoarthritis of the knee, J. Rheumatol. 26, 2659–2683.PubMedGoogle Scholar
  208. Graham, D. Y. and Smith, J. L. (1985). Effects of aspirin and an aspirin–acetaminophen combination on the gastric mucosa of normal subjects, Gastroenterology 88, 1922–1925.PubMedGoogle Scholar
  209. Graham, D. Y., White, R. H., Moreland, L. W., et al. (1993). Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs, Ann. Intern. Med. 119, 257–262.PubMedGoogle Scholar
  210. Graham G. G., Day R. O., Milligan M. K., et al. (1999). Current concepts of the actions of paracetamol (acetaminophen) and NSAIDs, Inflammopharmacology 7, 255–263.Google Scholar
  211. Grayson, M. F. (1978a). Two trials of diflunisal in osteoarthritis, Curr. Med. Res. Opin. 5, 567–571.PubMedGoogle Scholar
  212. Grayson, M. F. (1978b). A clinical trial of diflunisal against aspirin in osteoarthritis, Rheum. Rehab. 17, 265–269.Google Scholar
  213. Grecomoro, G., Martorana, U. and DiMarco, C. (1987). Intra-articular treatment with sodium hyaluronate in gonarthrosis: a controlled clinical trial versus placebo, Pharmatherapeutica 5, 137–141.PubMedGoogle Scholar
  214. Greenberg, H. E., Gottesdiener, K., Huntington, M., et al. (2000). A new cyclooxygenase-2inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers, J. Clin. Pharmacol. 40 (12 Pt 2), 1509–1515.PubMedGoogle Scholar
  215. Griffin, M. R., Brandt, K. D., Liang, M. H., et al. (1995). Practical management of osteoarthritis. Integration of pharmacological and nonpharmacologic measures, Arch. Fam. Med. 4, 1049–1055.PubMedGoogle Scholar
  216. Griswald, D. E. and Adams, J. L. (1996). Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date, Med. Res. Rev. 16 (2), 181–206.PubMedGoogle Scholar
  217. Guan, Y., Chang, M., Cho, W., et al. (1997). Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells, Am. J. Physiol. 273, F18–F26.PubMedGoogle Scholar
  218. Guidelines for the diagnosis, investigation and management of osteoarthritis of the hip and knee. Report of a joint working group of the British Society for Rheumatology and the Research Unit of the Royal College of Physicians. (1993). J. Roy. Coll. Physicians Lond. 27, 391–396.Google Scholar
  219. Hardin, J. G. and Kirk, K. A. (1979). Comparative effectiveness of five analgesics for the pain of rheumatoid arthritis, J. Rheumatol. 6, 405–442.PubMedGoogle Scholar
  220. Harper, S., Lee, M., Curtis, S., et al. (2001). A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs), Arthritis Rheum. 44, abstract 1590, S318.Google Scholar
  221. Harris, R. C., McKanna, J., Akai, Y., et al. (1994). Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction, J. Clin. Invest. 94, 2504–2510.PubMedGoogle Scholar
  222. Hart, D. J., Doyle, D. V. and Spector, T. D. (1999). Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study, Arthritis Rheum. 42, 17–24.PubMedGoogle Scholar
  223. Hart, F. D. (1987). Rational use of analgesics in the treatment of rheumatic disorders, Drugs 33, 85–93.Google Scholar
  224. Hawker, G., Wright, J., Coyle, P., et al. (1998). Health-related quality of life after knee replacement, J. Bone. Jt. Surg. 80A, 163–173.Google Scholar
  225. Hawkey, C. J. (1999). COX-2 inhibitors, Lancet 353, 307–314.PubMedGoogle Scholar
  226. Hawkey, C. J., Kahan, A., Steinbruck, K., et al. (1998a). Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxi-cam Large-scale International Study Safety Assessment, Brit. J. Rheumatol. 37, 937–945.Google Scholar
  227. Hawkey, C. J., Karrasch, J. A. and Szczepanski, L. (1998b). Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs, New Engl. J. Med. 338, 727–734.PubMedGoogle Scholar
  228. Hawkey, C., Laine, L., Mortensen, E., et al. (1999). Treatment of osteoarthritis with rofecoxib, a cyclooxygenase-2 (COX-2) specific inhibitor, was associated with a lower incidence of gas-troduodenal ulcers compared to ibuprofen and was comparable to placebo treatment, Ann. Rheum. Dis. (EULAR) p. 207, Abstract 861.Google Scholar
  229. Henderson, E. B., Smith, E. C., Pegley, F., et al. (1994). Intra-articular injection of a 750 kD. hyaluronan in the treatment of osteoarthritis: a randomized single center double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy, Ann. Intern. Med. 53, 529–534.Google Scholar
  230. Henry, D., Lim, L. L., Garcia Rodriguez, L. A., et al. (1996). Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis, Brit. Med. J. 312, 1563–1566.PubMedGoogle Scholar
  231. Herman, J. H., Appel, A. M. and Hess, E. V. (1987). Modulation of cartilage destruction by select non-steroidal anti-inflammatory drugs, Arthritis Rheum. 30, 257–265.PubMedGoogle Scholar
  232. Higgs, G. A. (1980). Arachidonic acid metabolism, pain and hyperalgesia: the mode of action of non-steroid analgesics, Br. J. Clin. Pharmacol. 10, 233S–235S.PubMedGoogle Scholar
  233. Highton, J. and Grahame, R. (1980). Benoxaprofenin the treatment of osteoarthritisq—A comparison with ibuprofen, J. Rheum. 7 (Suppl.), 125–131.Google Scholar
  234. Hingorani, K. (1976). A comparative study of azapropazone and ibuprofen in the treatment of osteoarthritis of the knee, Curr. Med. Res. Opin. 4, 57–64.PubMedGoogle Scholar
  235. Hla, T. and Neilson, K. (1992). Human cyclooxygenase-2 DNA, Proc. Natl. Acad. Sci. USA 89, 7384–7388.PubMedGoogle Scholar
  236. Hochberg, M. C., Altman, R. D., Brandt, K. D., et al. (1995a). Guidelines for the medical management of osteoarthritis. Part I Osteoarthritis of the hip. American College of Rheumatology, Arthritis Rheum. 38, 1535–1540.PubMedGoogle Scholar
  237. Hochberg, M. C., Altman, R. D., Brandt, K. D., et al. (1995b). Guidelines for the medical management of osteoarthritis. Part II Osteoarthritis of the knee. American College of Rheumatology, Arthritis Rheum. 38, 1541–1546.PubMedGoogle Scholar
  238. Hochberg, M. C., Altman, R. D., Brandt, K. D., et al. (1997). Design and conduct of clinical trials in osteoarthritis. Preliminary recommendations from a task force of the Osteoarthritis Research Society, J. Rheumatol. 24, 792–794.PubMedGoogle Scholar
  239. Hodler, J., Trudell, D., Pathria, M. N., et al. (1992). Width of the articular cartilage of the hip: quantification by using fat-suppression spin-echo MR imaging in cadavers, Am. J. Roentgenol. 159, 351–355.Google Scholar
  240. Hosie, J., Distel, M. and Bluhmki, E. (1997). Efficacy and tolerabilityof meloxicamversus piroxicam in patients with osteoarthritis of the hip and knee, Clin. Drug Invest. 13, 175–184.Google Scholar
  241. Hubbard, R., Geis, G. S., Woods, E., et al. (1998). Efficacy, tolerability, and safety of Celecoxib, a specific COX-2 inhibitor in osteoarthritis, Arthritis Rheum. 41 (Suppl. 9), S196. Abstract 982.Google Scholar
  242. Hui, X., Hewitt, P. G., Poblete, N., et al. (1998). In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers, Pharm. Res. 15 (10), 1589–1595.PubMedGoogle Scholar
  243. Hungin, A. P. S. and Kean W. F. (2001). Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis?, Amer. J. Med. 110, 8s–11s.PubMedGoogle Scholar
  244. Hurley, M. V. and Scott, D. L. (1998). Improvements in quadriceps sensorimotor function and disability of patients with knee osteoarthritis following a clinically practicable exercise regime, Br. J. Rheumatol. 37, 1181–1187.PubMedGoogle Scholar
  245. Huskisson, E. C. (1974). Simple analgesics for arthritis, Br. Med. J. 4, 196–200.PubMedGoogle Scholar
  246. Huskisson, E. C. and Donnelly, S. (1999). Hyaluronic acid in the treatment of osteoarthritis of the knee, Rheumatology 38, 602–607.PubMedGoogle Scholar
  247. Huskisson, E. C. and Scott, J. (1976). How double-blind is double-blind? And does it matter, Br. J. Clin. Pharmacol. 3, 331–332.PubMedGoogle Scholar
  248. Huskisson, E. C. and Scott, J. (1978). Sulindac. Trials of a new anti-inflammatory drug, Ann. Rheum. Dis. 37, 89–92.PubMedGoogle Scholar
  249. Huskisson, E. C., Berry, P. G., Gishen, P., et al. (1995). Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal investigation of nonsteroidal anti inflammatory drugs in knee osteoarthritis, J. Rheumatol. 22, 1941–1946.PubMedGoogle Scholar
  250. Hyleh, E. M., Heiman, H., Skates, S. J., et al. (1998). Acetaminophen and other risk factors for excessive warfarin anticoagulants, J. Amer. Med. Assoc. 279, 702–703.Google Scholar
  251. IMS Health (1999). www.ims-global.com/insight/news_story/news_story_000330a.htm— 15kGoogle Scholar
  252. IMS Health, Canada (1999). www.imshealthcanada.com/htmen/4_2_1_14.htm — 15kGoogle Scholar
  253. Ivey, K. J. (1986). Gastrointestinal intolerance and bleeding with non-narcotic analgesics, Drugs 32 (Suppl. 4), 71–79.Google Scholar
  254. Jamison, R. N., Anderson, K. O., Peeters-Asdourian, C., et al. (1994). Survey of opioid use in chronic nonmalignant pain patients, Reg. Anesth. 19, 225.PubMedGoogle Scholar
  255. Jankovic, D. and Wells, C. (2001). Regional Nerve Blocks. Blackwell Science, Berlin.Google Scholar
  256. Jeal, W. and Benfield, P. (1997). Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control, Drugs 53, 109–138.PubMedGoogle Scholar
  257. Jobanputra, P. and Nuki, G. (1994). Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis, Curr. Opin. Rheumatol. 6, 433–439.PubMedGoogle Scholar
  258. Johnson, E. E. and Urist, M. R. (1998). One stage lengthening of femoral nonunion augmented with human bone morphogenetic protein, Clin. Orthop. 347, 105–116.PubMedGoogle Scholar
  259. Johnson, E. E. and Urist, M. R. (2000). Human bone morphogenetic protein allografting for reconstruction of femoral nonunion, Clin. Orthop. 371, 61–74.PubMedGoogle Scholar
  260. Johnson, E.E, Urist, M. R. and Finerman, G. A. (1992). Resistant nonunions and partial or complete segmental defects in long bones. Treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen extracted, allogenic (AAA) bone, Clin. Orthop. 277, 229–237.PubMedGoogle Scholar
  261. Jones, D. A., Carleton, D. P., McIntyre, T. M., et al. (1993). Molecular cloning of human prostaglandin endoperoxide synthase type II, and demonstration of expression in response to cytokines, J. Biol. Chem. 268, 9049–9054.PubMedGoogle Scholar
  262. Joubert, P. H., Kushlick, A. R., McNeill, W. G., et al. (1974). South African multicentre trial with Voltaren in osteo-arthritis of the knee, S. African Med. J. 48, 1973–1978.Google Scholar
  263. Jouzeau, J. Y., Terlain, B., Abid, A., et al. (1997). Cyclooxygenase isoenzymes: how recent findings affect thinking about non-steroidal anti-inflammatory drugs, Drugs 53 (4), 563–582.PubMedGoogle Scholar
  264. Juni, P., Rutjes, A. W. and Dieppe, P. A. (2002). Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?, BMJ 324, 1287–1288.PubMedGoogle Scholar
  265. Kamali, F. (1993). The effect of probencid on paracetamol metabolism and pharmacokinetics, Eur. J. Clin. Pharmacol. 45, 551–553.PubMedGoogle Scholar
  266. Kamali, F., Fry, J. R., Smart, H. L., et al. (1985). A double-blind placebo-controlledstudy to examine effects of sulcrafate on paracetamol absorption, Br. J. Clin. Pharmacol. 19, 113–114.PubMedGoogle Scholar
  267. Kang, R., Ghivizzani, S. C., Muzzonigro, T. S., et al. (2000). Orthopaedic applications of gene therapy — from concept to clinic, Clin. Orthop. Rel. Res. 375, 324–337.Google Scholar
  268. Kantor, T. G. (1980). Analgesics for arthritis, Clin. Rheum. 6, 525–531.Google Scholar
  269. Kaps, C., Bramlage, C., Smolian, H., et al. (2002). Bone morphogenetic proteins promote cartilage differentiation and protect engineered artificial cartilage from fibroblast invasion and destruction, Arthritis Rheum. 46, 149–162.PubMedGoogle Scholar
  270. Kean, W. F. and Buchanan, W. W. (1987). Variables affecting the absorption of non-steroidal anti-infl ammatory drugs from the gastrointestinal tract, Japan J. Rheumatol. 1(3), 159–170.Google Scholar
  271. Kean, W. F., Lock, C. J. L., Rischke, J., et al. (1989). Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets, J. Pharm. Sci. 78, 324–327.PubMedGoogle Scholar
  272. Kean, W. F., Buchanan, W. W. and Rainsford, K. D. (1999). Therapeutics of ibuprofen in rheu-matic and other chronic and painful diseases, in: Ibuprofen. A Critical Bibliographic Review, K. D. Rainsford (Ed.), Chapter 6, pp. 277–353. Taylor and Francis, London.Google Scholar
  273. Keating, E. M., Faris, P. M., Ritter, M. A., et al. (1993). Use of lateral heel and sole wedges in the treatment of medial osteoarthritis of the knee, Orthopaedic Rev. 22, 921–924.Google Scholar
  274. Kessler, D. A., Siegel, J. P., Noguchi, P. D., et al. (1993). Regulation of somatic-cell therapy and gene therapy by the food and drug administration, N. Engl. J. Med. 329, 1169–1173.Google Scholar
  275. Kidd B. L., Cruwys S., Mapp P. I., et al. (1992). Role of the sympathetic nervous system in chronic joint pain and inflammation, Ann. Rheum. Dis. 51, 1188–1191.PubMedGoogle Scholar
  276. Kivitz, A., Eisen, G., Zhao, W. W., et al. (2001). The cox-2 specific inhibitor valdecoxib is as effective as the conventional NSAID naproxen in treating symptomatic osteoarthritis of the knee and demonstrates reduced gastrointestinal ulceration, Arthritis Rheum. 44 (Suppl. 9), abstract 500, S136.Google Scholar
  277. Klein, B. (1982). Carpofen in osteoarthritis, Europ. J. Rheum. Inflame. 5, 507–513.Google Scholar
  278. Knowles, S., Shapiro, L. and Shear, N. H. (2001). Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy, Drug Safiety 24(4), 239–247.Google Scholar
  279. Koch, M., Dezi, A., Ferraris F., et al. (1996). Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosa injury. A meta-analysis of randomized controlled clinical trials, Arch. Int. Med. 156, 2321–2332.Google Scholar
  280. Komhoff, M., Groen, H. J., Klein, T., et al. (1997). Localization of cyclooxygenase-1 and-2 in adult and foetal human kidney: implication for renal function, Am. J. Physiol. 272, F460–F468.PubMedGoogle Scholar
  281. Komistek, R. D., Dennis, D. A., Northcut, E. J., et al. (1999). An in vivo analysis of the effectiveness of the osteoarthritic knee brace during heel-strike of gait, J. Arthroplasty 14, 738–742.PubMedGoogle Scholar
  282. Konttinen, Y. T., Kemppinen, P., Segerberg, M., et al. (1994). Peripheral and neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain, Arthritis Rheum. 37, 965–982.PubMedGoogle Scholar
  283. Konturek, S. J., Piastucki, I., Brzozowski, T., et al. (1981). Role of prostaglandin in the formation of aspirin-induced ulcers, Gastrointerology 80, 4–9.Google Scholar
  284. Kosinski, M., Kujawski, S. C., Martin, R., et al. (2002). Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response, Am. J. Manag. Care. 8, 231–240.PubMedGoogle Scholar
  285. Kovar, P. A., Allegrante, J. P., MacKenzie, C. R., et al. (1992). Supervised fitness training in patients with osteoarthritis of the knee: a randomized, controlled trial, Ann. Intern. Med. 116, 529–534.PubMedGoogle Scholar
  286. Kurumbail, R. G., Stevens, A. M., Gierse, et al. (1996). Structural basis for selective inhibition of cyclooxygenase by anti-inflammatory agents, Nature 384, 644–648.Google Scholar
  287. Kwan, D. and Bartle, W. R. (1993). Drug interactions with warfarin, Med. J. Aust. 158, 574–575.Google Scholar
  288. Laine, L., Harper, S., Simon, T., et al. (1999). For the Rofecoxib Osteoarthritis Endoscopy Study Group. A randomized trila comparing the effect of rofecoxib, a cyclooxygenase 2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis, Gastroenterology 117, 776–783.PubMedGoogle Scholar
  289. Lambert, J. R., Cardon, N., Simpson, N. R., et al. (1985). A controlled comparison of tiaprofenic acid and ibuprofen in osteoarthritis, Int. J. Clin. Pharm. Res. 5, 161–164.Google Scholar
  290. Langley, G. B. and Sheppard, H. (1984). Problems associated with pain measurement in arthritis; comparison of visual analogue and verbal rating scales, Clin. Exp. Rheumatol. 2, 231–234.PubMedGoogle Scholar
  291. Langman, M., Jensen, D. and Watson, D. J. (1999a). Lower incidence of clinically evident upper GI perforation, ulcers, and bleeds in patients treated with rofecoxib versus non-specific cyclooxyge-nase inhibitors, Ann. Rheum. Dis. (EULAR) p. 207, Abstract 862.Google Scholar
  292. Langman, M. J., Jensen, D. M., Watson, D. J., et al. (1999b). Adverse upper gastrointestinal effects of rofecoxib with NSAIDs, J. Am. Med. Assoc. 282, 1929–1933.Google Scholar
  293. Ledingham, J., Dawson, S., Preslon, B., et al. (1993a). Radiographic progression of hospital referred osteoarthritis of the hip, Ann. Rheum. Dis. 52, 263–267.PubMedGoogle Scholar
  294. Ledingham, J., Regan, M., Jones, A., et al. (1993b). Radiographic patterns and associations of osteoarthritis of the knee in patients referred to hospital, Ann. Rheum. Dis. 52, 520–526.PubMedGoogle Scholar
  295. Ledley, F. D. (1994). Therapeutic promise of molecular genetics, J. Invest. Dermatol. 103 (5 Suppl.), 2S–5S.PubMedGoogle Scholar
  296. Lee, P., Anderson, J. A., Miller, J., et al. (1976). Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis, J. Rheumatol. 3, 283–295.PubMedGoogle Scholar
  297. Lequesne, M. G. (1987). The algofunctional indices for hip and knee osteoarthritis, J. Rheumatol. 24, 779–781.Google Scholar
  298. Lequesne, M. G., Mery, C., Samson, M., et al. (1987). Indexes of severity for osteoarthritis of the hip and knee, Scan. J. Rheumatol. 65 (Suppl), 85–89.Google Scholar
  299. Lequesne, M., Brandt, K., Bellamy, N., et al. (1994). Guidelines for testing slow-acting and disease-modifying drugs in osteoarthritis, J. Rheumatol. 21 (Suppl. 41), 65–71.Google Scholar
  300. Lipsky, L. P. E., Abramson, S., Crofford, L., et al. (1998). The classification of cyclooxygenase inhibitors, J. Rheumatol. 25, 2298–2303.PubMedGoogle Scholar
  301. Lloyd-Roberts, G. C. (1953). The role of capsular changes in osteoarthritis of the hip joint, J. Bone Jt. Surg. 35B, 627–642.Google Scholar
  302. Lohmander, L. S. (1994). Articular cartilage and osteoarthritis: the role of molecular markers to monitor breakdown, repair and disease, J. Anat. 184, 477–492.PubMedGoogle Scholar
  303. Lohmander, L. S. and Felson, D. T. (1997). Defining the role of molecular markers to monitor disease, intervention, and cartilage breakdown in osteoarthritis, J. Rheumatol. 24, 782–785.PubMedGoogle Scholar
  304. Lorig, K., Lubeck, D., Kraines, R. G., et al. (1985). Outcomes of self-help education for patients with arthritis, Arthritis Rheum. 28, 680–685.PubMedGoogle Scholar
  305. Lorig, K. R., Mazonson, P. D. and Holman, H. R. (1993). Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs, Arthritis Rheum. 36, 439–446.PubMedGoogle Scholar
  306. Lotz, M. (1999). The role of nitric oxide in articular cartilage damage, Rheum. Dis. Clinics N. Amer. 25, 269–282.Google Scholar
  307. Luggen, M. E., Gartside, P. S. and Hess, E. V. (1989). Nonsteroidal anti-inflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value, J. Rheumatol. 16, 1565–1569.PubMedGoogle Scholar
  308. Lund, B., Distel, N. and Bluhmki, E. (1998). A double-blind randomized, placebo-controlledstudy of efficacy and tolerance of meloxicamtreatment in patients with osteoarthritis of the knee, Scand. J. Rheum. 27, 32–37.PubMedGoogle Scholar
  309. Luong, C., Miller, A., Barnett, J., et al. (1996). Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2, Nature Sctrct. Biol. 3, 927–933.Google Scholar
  310. Lynch, J. M. and Fox, T. M. (2001). Use of acetaminophen in the treatment of osteoarthritis in patients with liver disease: comment on the 2000 update of the American College of Rheumatology recommendationsfor management of hip and knee osteoarthritis, Arthritis Rheum. 44, 2448–2449.PubMedGoogle Scholar
  311. Makarowski, W., Zhao, W. W., Bevirt, T., et al. (2001). The COX-2 specific inhibitor valdecoxib is effective in treating symptomatic osteoarthritis of the hip, Arthritis Rheum. 44 (Suppl. 9), abstract 492, S134.Google Scholar
  312. Manchester General Practitioner Group (1984). A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice, Curr. Med. Res. Opin. 9, 41–46.Google Scholar
  313. March, L. (1997). Osteoarthritis, Med. J. Aust. 166, 98–103.PubMedGoogle Scholar
  314. March, L., Irwig, L., Schwarz, J. et al. (1994). n of 1 trials comparing a non-steroidal anti-infl ammatory drug with paracetamol in osteoarthritis, Br. Med. J. 309, 1041–1045.Google Scholar
  315. Marks, R. (1994). Reliability and validity of self-paced walking time measures for knee osteoarthritis, Arthritis Care Res. 7, 50–53.PubMedGoogle Scholar
  316. Marsepiol, T., Mahassani, B., Roudiak, N., et al. (1989). Potentialisation de la toxicity hépatique et rénale du paracétamol par le phénnobarbital, JEUR 2, 118–120.Google Scholar
  317. Martin, R. M., Biswas, P. and Mann, R. D. (2000). The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study, Br. J. Clin. Pharmacol. 50, 35–42.PubMedGoogle Scholar
  318. Martinez, L. M., Homan, K. I., Smyth, C. J., et al. (1980). A comparison of naproxen, indomethacin and aspirin in osteoarthritis, J. Rheum. 7, 711–716.PubMedGoogle Scholar
  319. Masferrer, J. L., Zweipel, B. S., Seibert, K., et al. (1990). Selective regulations of cellular cyclooxy-genase by dexamethasone and endotoxin in mice, J. Clin. Invest. 86, 1375–1379.PubMedGoogle Scholar
  320. Mather, L. E., Tucker, G. T., Pflug, A. E., et al. (1975). Meperidine kinetics in man, Clin. Pharmacol. Ther. 17, 21–31.PubMedGoogle Scholar
  321. Maulding, T. S., Redeker, A. C. and Kanel, G. C. (1989). Twenty isoniazid-associateddeaths in one state, Am. Rev. Respir. Dis. 140, 700–705.PubMedGoogle Scholar
  322. Maulding, T. S., Redeker, A. G. and Kanel, G. C. (1991). Acetaminophen, isoniazid, and hepatic toxicity, Ann. Intern. Med. 114, 431.Google Scholar
  323. Maurer, B. T., Stern, A. G., Kinossian, B., et al. (1999). Osteoarthritis of the knee: isokinetic quadriceps exercise versus an educational intervention, Arch. Phys. Med. Rehab. 80, 1293–1299.Google Scholar
  324. Max, M. B., Schafer, S. C., Culnane, M., et al. (1988). Associationof pain relief with drug side-effects in post hepatic neuralgia, Clin. Pharmacol. Ther. 43, 363–371.PubMedGoogle Scholar
  325. Mazzuca, S. A., Brandt, K. D., Katz., B. P., et al. (1993). Therapeutic strategies distinguish com-monly based primary care physicians from rheumatologists in the management of osteoarthritis, J. Rheumatol. 20, 80–86.PubMedGoogle Scholar
  326. Mazzuca, S. A., Brandt, K. D. and Katz, B. P. (1997a). Is conventional radiography suitable for evaluation of a disease-modifying drug in patients with knee osteoarthritis?, Osteoarthritis Cartilage 5, 217–226.PubMedGoogle Scholar
  327. Mazzuca, S. A., Brandt., K. D. and Katz, B. P. (1997b). Effects of self-care education on the health status of inner-city patients with osteoarthritis of the knee, Arthritis Rheum. 40, 1466–1474.PubMedGoogle Scholar
  328. Mazzuca, S. A. and Brandt, K. D. (1999). Plain radiography as a outcome measure in clinical trials involving patients with knee osteoarthritis, Rheum. Dis. Clin. N. Am. 54, 467–480.Google Scholar
  329. Mazzuca, S. A., Brandt, K. D., Katz, B. P., et al. (1999). Reduced utilization and cost of primary care clinic visits resulting form self-care education for patients with osteoarthritis of the knee, Arthritis Rheum. 42, 1267–1273.PubMedGoogle Scholar
  330. McAlindon, T. and Dieppe, P. (1990). The medical management of osteoarthritis of the knee: an inflammatory issue?, Br. J. Rheumatol. 29, 471–473.PubMedGoogle Scholar
  331. McAlindon, T. E., LaValley, M. P., Gulin, J. P., et al. (2000). Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis, J. Amer. Med. Assoc. 283, 1469–1475.Google Scholar
  332. McCarthy, G. M. and McCarty, D. J. (1992). Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands, J. Rheumatol. 19, 604–617.PubMedGoogle Scholar
  333. McClain, C. J., Kromhout, J. P. and Peterson, F. J. (1980). Potentiation of acetaminophen hepatotoxi-city by alcohol, JAMA 244, 251–253.PubMedGoogle Scholar
  334. McDermott, F. T. (1985). Mortality from bleeding peptic ulcer. Alfred Hospital Melbourne, 1976–1980, Med. J. Aust. 142, 11–14.Google Scholar
  335. McMahon, F. G., Jain, A. and Orel, A. (1976). Controlled evaluationof fenoprofenin geriatric patients with osteoarthritis, J. Rheum. 3 (Suppl.), 76–82.Google Scholar
  336. McPherson, K., Britton, A. R. and Wenneberg, J. E. (1997). Are randomized controlled trials controlled? Patient preferences and unblind trials, J. Roy. Soc. Med. 90, 652–656.Google Scholar
  337. McQuay, H. and Moore, A. (1999a). Topically applied non-steroidal anti-inflammatory drugs, in: An Evidenced-based Resource for Pain Relief, pp. 102–117. Oxford University Press, Oxford, UK.Google Scholar
  338. McQuay, H. and Moore, A. (1999b). An Evidenced Based Resource for Pain Relief, pp. 58–77, 138–146. Oxford University Press, Oxford, UK.Google Scholar
  339. Meenan, R. F., Gertmann, P. N. and Mason, H. (1980). Measuring health status in arthritis: the Arthritis Impact Measurement Scales, Arthritis Rheum. 23, 146–152.PubMedGoogle Scholar
  340. Melander, O., Lidén, A. and Melander, A. (1995). Pharmacokinetic interaction of alcohol and acetylsalicylic acid, Eur. J. Clin. Pharmacol. 48, 151–153.PubMedGoogle Scholar
  341. Melton, J. W. 3rd, Lussier, A., Ward, J. R., et al. (1978). Naproxen vs. aspirin in osteoarthritis of the hip and knee, J. Rheum. 5, 338–346.PubMedGoogle Scholar
  342. Mengle-Law, L., Hubbard, R. C., Karim, A., et al. (1997). A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor, Arthritis Rheum. 40 (Suppl. 9), 593.Google Scholar
  343. Michalets, E. L. (1998). Update: Clinically significant cytochrome P450 drug interactions, Pharma-cotherapy 18, 84–112.Google Scholar
  344. Mills, S. Y., Jacoby, R. K., Chacksfield, M., et al. (1996). Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: a double-blind study, Br. J. Rheumatol. 35 (9), 874–878.PubMedGoogle Scholar
  345. Miners, J. O., Attwood, J. and Birkett, D. J. (1983). Influence of sex and oral contraceptive steroids on paracetamol metabolism, Br. J. Clin. Pharmacol. 16, 503–509.PubMedGoogle Scholar
  346. Miners, J. O., Attwood, J. and Birkett, D. J. (1984). Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways, Clin. Pharmacol. Ther. 35, 480–486.PubMedGoogle Scholar
  347. Minor, M. A. (1994). Exercise in the management of osteoarthritis of the knee and hip, Arthritis Care and Research. 7, 198–204.PubMedGoogle Scholar
  348. Minor, M. A. (1999). Exercise in the treatment of osteoarthritis, Rheum. Dis. Clinics North Amer. 25, 397–415.Google Scholar
  349. Mitchell, M. C., Hanew, T., Meredith, C. G., et al. (1983). Effects of oral contraceptive steroids on acetaminophen metabolism and elimination, Clin. Pharmacol. Ther. 34, 48–53.PubMedGoogle Scholar
  350. Moore, R. A., Tramer, M., Carroll, D., et al. (1998). Quantitative systematic review of topically applied nonsteroidal anti-inflammatory drugs, Br. Med. J. 316, 333–338.Google Scholar
  351. Moulding, T. S., Redeker, A. G. and Kanel, G. C. (1989). Twenty isoniazid-associateddeaths in one state, Am. Rev. Respir. Dis. 140, 700–705.PubMedGoogle Scholar
  352. Moulding, T. S., Redeker, A. G. and Kanel G. C. (1991). Acetaminophen, isoniazid, and hepatic toxicity, Ann. Intern. Med. 114, 431.Google Scholar
  353. Moxley, T. E., Royer, G. L., Hearron M. S., et al. (1975). Ibuprofen verus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial, J. Am. Ger. Soc. 23, 343–349.Google Scholar
  354. Mucklow, J. C., Fraser, H. S., Bulpitt, C. J., et al. (1980). Environmental factors affecting paracetamol metabolismon London factory and office workers, Br. J. Clin. Pharmacol. 10, 67–74.PubMedGoogle Scholar
  355. Mullen, B. J. (1987). Results of a six-month study comparing the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis, Am. J. Med. 83, 74–77.Google Scholar
  356. Muller, F. O., Gosling, J. A. and Erdmann, G. H. (1977). A comparison of tolmetin with aspirin in the treatment of osteo-arthritis of the knee, South African Medical Journal 51, 794–796.PubMedGoogle Scholar
  357. Müller-Fassbender, H. (1987). Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis, Am. J. Med. 83, 81–83.PubMedGoogle Scholar
  358. Murphy, R., Swartz, R. and Watkins, P. B. (1990). Severe acetaminophentoxicity in a patient receiving isoniazid, Ann. Inter. Med. 113, 799–800.Google Scholar
  359. Myers, S. L. (1999). Synovial fluid markers in osteoarthritis, Rheum. Dis. Clinics North Amer. 25, 433–449.Google Scholar
  360. Myers, S. L., Dines, K., Brandt, D. A., et al. (1995). Assessment by high frequency ultrasound of articular cartilage thickness and osteoarthritic changes, J. Rheumatol. 22, 109–116.PubMedGoogle Scholar
  361. Naylor, C. D. and Williams, J. I. (1996). Primary hip and knee replacement surgery: Ontario criteria for case selection and surgical priority, Quality of Health Care 5, 20–30.Google Scholar
  362. Needleman, P. and Isakson, P. C. (1997). The discovery and function of COX-2, J. Rheumatol. 24 (Suppl. 49), 6–8.PubMedGoogle Scholar
  363. Newman, N. M. and Ling, R. S. (1985). Acetabular bone destruction related to non-steroidal anti-infl ammatory drugs, Lancet 2, 11–14.PubMedGoogle Scholar
  364. Newman, S. P. (1997). Psychosocial measures in musculoskeletal trials, J. Rheumatol. 24, 979–984.PubMedGoogle Scholar
  365. Nimmo, J., Heading, R. C., Tothill, P., et al. (1973). Pharmacological modification of gastric emptying effects of propantheline and metoclopromide on paracetamol absorption, Br. Med. J. 1, 587–589.PubMedGoogle Scholar
  366. Nimmo, W. S., Heading, R. C., Wilson, J., et al. (1975a). Inhibition of gastric emptying and drug absorption by narcotic analgesics, Br. J. Clin. Pharmacol. 2, 509–513.PubMedGoogle Scholar
  367. Nimmo, W. S., Wilson, J. and Prescott, L. F. (1975b). Narcotic analgesics and delayed gastric emptying during labour, Lancet 1, 890–893.PubMedGoogle Scholar
  368. Nolan, C. M., Sandbloom, R. E., Thummel, K. E., et al. (1994). Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis, Chest 105, 408–411.PubMedGoogle Scholar
  369. Nolan, L. and O'Malley, K. (1988). Prescribing for the elderly. Part II. Prescribing patterns: differences due to age, J. Am. Geriatric Soc. 36, 245–254.Google Scholar
  370. Nuki, G. (1983). Non-steroidal analgesics and anti-inflammatory agents, Brit. Med. J. 287, 39–43.Google Scholar
  371. Nuki, G. (1990). Pain control and the use of non-steroidal anti-inflammatory drugs, Br. Med. Bull. 308, 262–278.Google Scholar
  372. Nuki, G., (1993). The effects of non-steroidal anti-inflammatory drugs on cartilage and connective tissue, in: Intermittent High Intensity Exercise, D. A. D. Macleod, R. J. Maughan, C. Williams, C. R. Madeley, C. J. M. Sharp and R. W. Hutton (Eds), pp. 339–351. E and FN Spon, London.Google Scholar
  373. Nuki, G., Downie, W. W., Dick, W. C., et al. (1973). Clinical trial of pentazocine in rheumatoid arthritis. Observations in the values of potent analgesics and placebos, Ann. Rheum. Dis. 32, 436–443.PubMedGoogle Scholar
  374. O'Brien, W. M. and Bagby, G. F. (1985). Rare adverse reactions to nonsteroidal anti-inflammatory drugs, J. Rheumatol. 12, 562–567.PubMedGoogle Scholar
  375. O'Callaghan, C. A., Andrews, P. A. and Ogg, C. S. (1994). Renal disease and use of topical non-steroidal anti-inflammatory drugs, Br. Med. J. 308, 110–111.Google Scholar
  376. O'Reilly, S. C., Muir, K. R. and Doherty, M. (1996). Screening for pain in knee osteoarthritis: which question?, Ann. Rheum. Dis. 55, 931–933.PubMedGoogle Scholar
  377. O'Reilly, S. C., Muir, K. R. and Doherty, M. (1999). Effectiveness of home exercise on pain and disability from osteoarthritis of the knee: a randomized controlled trial, Ann. Rheum. Dis. 58, 15–19.PubMedGoogle Scholar
  378. Ogata, K., Yasunaga, M. and Nomiyama, H. (1997). The effect of wedged insoles on the thrust of osteoarthritic knees, Int. Orthopaed. 21, 308–312.Google Scholar
  379. Ouslander, J. G. (1981). Drug therapy in the elderly, Ann. Int. Med. 95, 711–722.PubMedGoogle Scholar
  380. Pahor, M., Guralnik, J. M., Wan, J Y., et al. (1999). Lower body osteoarthritis pain and dose of analgesic medications in older disabled women: The Women's Health and Aging Study, Am. J. Public. Health 89, 930–934.PubMedGoogle Scholar
  381. Palmoski, M. J., Colyer, R. and Brandt, K. D. (1980). Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritic cartilage, Arthritis Rheum. 23, 83–91.PubMedGoogle Scholar
  382. Pariet, M., Van Ryn, J., Mauz, A., et al. (1997). Differential inhibitors of COX-1 and COX-2 by NSAIDs: a summary of results obtainedusing various test systems, in: Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic Potential, J. Vane and J. Botting (Eds), Vol. 3, pp. 27–46. Kluwer Academic Publishers, Dordrecht.Google Scholar
  383. Parr G., Darekar B., Fletcher A., et al. (1989). Joint pain and quality of life; results of a randomised trial, Br. J. Clin. Pharmacol. 27, 235–242.PubMedGoogle Scholar
  384. Patterson, R., Bello, A. E. and Lefkowith, J. (1999). Immunologic tolerability profile of celecoxib, Clin. Ther. 21(12), 2065–2079.PubMedGoogle Scholar
  385. Pelletier, J. P., Mineau, F., Raynaud, J. P., et al. (1994). Intra articular injections with methylpred-nisolone acetate reduce osteoarthritic lesions in parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis, Arthritis Rheum. 37, 414–423.PubMedGoogle Scholar
  386. Pelletier, J. P., Caron, J. P., Evans, C., et al. (1997). In Vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy, Arthritis Rheum. 40, 1012–1019.PubMedGoogle Scholar
  387. Pelletier, J. P., Martel-Pelletier, J., Abramson, S. B., et al. (2001). Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets, Arthritis Rheum. 44, 1237–1247.PubMedGoogle Scholar
  388. Perucca, E. and Richens, A. (1979). Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs, Br. J. Pharmacol. 7, 201–206.Google Scholar
  389. Peterson, M. G. E., Kovar-Toledano, P. A., Otis, J. C., et al. (1993). Effect of a walking program on gait characteristics in patients with osteoarthritis, Arthritis Care Res. 6, 11–16.PubMedGoogle Scholar
  390. Peterson, W. L. and Cryer, B. (1999). COX-1 sparing NSAIDs — is the enthusiasmjustified?, J. Am. Med. Assoc. 282, 1961–1963.Google Scholar
  391. Peyron, J. G. (1982). Double-blind comparative studies of tiaprofenic acid in degenerative joint diseases, J. Rheum. 7, 151–158.Google Scholar
  392. Pfeiffer, R. F. (1982). Drugs for pain in the elderly, Geriatrics 37, 67–76.PubMedGoogle Scholar
  393. Picot, D., Loll, P. J. and Garraviot, R. M. (1994). The x-ray crystal structure of the membrane protein prostaglandinH2 synthase-1, Nature 367, 243–249.Google Scholar
  394. Pipitone, V., Carrozzo, M. and Loizzi, P. (1973). A clinical study of Brufen in comparison with phenylbutazone and indomethacin. Abstracts of XIII International Congress of Rheumatology, Kyoto, p. 134.Google Scholar
  395. Pirotte, J. H. (1984). Apparent potentiation by phenobarbital of hepatoxicity from small doses of acetaminophen, Ann. Inter. Med. 101, 403.Google Scholar
  396. Poole, A. R. (1994). Immunochemical markers of joint inflammations, skeletal damage and repair: where are we now?, Ann. Rheum. Dis. 53, 3–5.PubMedGoogle Scholar
  397. Prescott, L. F., Critchlely, J. A. J. H., Balali-Mood, M., et al. (1981). Effects of microsomal induction on paracetamol metabolism in man, Br. J. Clin. Pharmacol. 12, 149–153.PubMedGoogle Scholar
  398. Preston S. J., Arnold, M. H., Beller, E. M., et al. (1989). Comparative analgesic and anti-inflammatory properties of sodium salicylate and acetyl salicylic acid (aspirin) in rheumatoid arthritis, Br. J. Clin. Pharmacol. 27, 607–611.PubMedGoogle Scholar
  399. Puett, D. W. and Griffin, M. R. (1994). Published trials of nonmedical and noninvasive therapies for hip and knee osteoarthritis, Ann. Intern. Med. 121, 133–140.PubMedGoogle Scholar
  400. Rashad, S., Revell, P., Hemingway, A., et al. (1989). Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis, Lancet 2, 519–522.PubMedGoogle Scholar
  401. Ratcliffe, A. and Seibel, M. J. (1990). Biochemical markers in osteoarthritis, Curr. Opin. Rheumatol. 2, 770–776.PubMedGoogle Scholar
  402. Ravaud, P., Moulinier, L., Giraudeau, B., et al. (1999). Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of multicenter, randomized, controlled trial, Arthritis Rheum. 42, 475–482.PubMedGoogle Scholar
  403. Reddi, A. H. (1992). Regulation of cartilage and bone differentiationby bone morphogenetic proteins, Curr. Opin. Cell Biol. 4, 850–855.PubMedGoogle Scholar
  404. Rennie, J. A. N., Mason, D. I. R. and Capell, H. A. (1977). Simple analgesics in rheumatoid arthritis. Editorial, Scot. Med. J. 22, 253–254.PubMedGoogle Scholar
  405. Richter, J. A., Runge, L. A., Pinals, R. S., et al. (1980). Analysis of treatment terminators with gold and antimalarial compounds in RA, J. Rheumatol. 7, 153–159.PubMedGoogle Scholar
  406. Riendeau, D., Percival, M. D., Brideau, C., et al. (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2, J. Pharmacol. Exp. Ther. 296(2), 558–566.PubMedGoogle Scholar
  407. Rinder, H. M., Gagnier, R. P., Souhrada, M., et al. (2001). Bleeding time and platelet function in normal volunteers receiving meloxicam. Abstract, EULAR. Google Scholar
  408. Roberts, M. S. and Cross, S. E. (1999). Percutaneous absorption of topically applied NSAIDs and other compounds: Role of solute properties, skin physiology and delivery systems, Inflammopharmacology 7, 339–350.Google Scholar
  409. Robertson, D. R. C., Higginson, I., Macklin, B. S., et al. (1991). The influence of protein-containing meals on the pharmacokinetics of levodopa in healthy volunteers, Br. J. Clin. Pharmacol. 31, 413–417.PubMedGoogle Scholar
  410. Rogers, S. M., Back, D. J., Stevenson, P., et al. (1987). Paracetamol intervention with oral contra-ception steroids: increased plasma concentration of ethinyloestradiol, Br. J. Clin. Pharmacol. 23, 721–725.PubMedGoogle Scholar
  411. Rosenbloom D., Brooks, P., Bellamy, N., et al. (1985). Clinical Trials in the Rheumatic Diseases, Praeger, New York.Google Scholar
  412. Ross, A. C. (1991). Infected arthroplasties, Curr. Opin. Rheumatol. 3, 628–633.PubMedGoogle Scholar
  413. Roth, S. H. (1998). Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis, J. Rheumatol. 25, 1358–1363.PubMedGoogle Scholar
  414. Rothstein, J. (1975). Phenylbutazone and aspirin in osteoarthritis — a controlled study, Curr. Ther. Res. 17, 444–451.PubMedGoogle Scholar
  415. Rovati, L. C. (1992). Clinical research in osteoarthritis: design and results of short-termand long-term trials with disease-modifying drugs, Int. J. Tissue Reactions 14, 243–251.Google Scholar
  416. Rubin, R. N., Mentzer, R. L. and Budzynski, A. Z. (1984). Potentiation of anticoagulant effect of warfarin by acetaminophen (Tylenol), Clin. Res. 32, 698.Google Scholar
  417. Ryan, M. E., Greenwald, R. A. and Golub, L. M. (1996). Potential of tetracyclines to modify cartilage breakdown in osteoarthritis, Curr. Opin. Rheumatol. 8, 238–247.PubMedGoogle Scholar
  418. Saag, K., Fisher, C., McKay, J., et al. (1998). MK-0966, a specific COX-2 inhibitor, has clinical efficacy, comparable to Ibuprofen in the treatment of knee and hip OA in a 6-week controlled clinical trial, Arth. Rheum. 41 (Suppl. 9), 584.Google Scholar
  419. Sacchetti, G., DiMurro, R., Mandelli, V., et al. (1978). Clinical testing of indoprofen in osteoarthritis: a controlled trial using a balanced incomplete block design, Curr. Ther. Res. 24, 274–283.Google Scholar
  420. Sackett, D. L., Richardson, W. S., Rosenberg, W., et al. (1998). Evidence-Based Medicine. Churchill Livingstone, Edinburgh.Google Scholar
  421. Sanha, O. and Liang, M. H. (1995). Assessment outcomes of clinical drug trials in osteoarthritis, Curr. Opin. Rheumatol. 7, 352–355.PubMedGoogle Scholar
  422. Scale, D., Wobig, M. and Wolpert, W. (1994). Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study, Curr. Ther. Res. 55, 220–232.Google Scholar
  423. Scharf, Y., Nahir, M., Schapera, D., et al. (1982). A comparative study of naproxen with diclofenac sodiumin osteoarthritis of the knee, Rheumatol. Rehabil. 21, 167–170.PubMedGoogle Scholar
  424. Scharff, U. (1974). A double-blind comparison of phenylbutazone and aspirin in osteoarthritis, Curr. Ther. Res. 16, 1264–1269.PubMedGoogle Scholar
  425. Scheiman, J. M. (1994). NSAID-induced peptic ulcer disease: a critical review of pathogenesis and management, Dig. Dis. 12(4), 210–222.PubMedGoogle Scholar
  426. Scheiman, J. M., Behler, E. M., Loeffler, K. M., et al. (1994). Omeprozole ameliorates aspirin-induced gastrointestinal injury, Dig. Dis. and Sci. 39, 97–103.Google Scholar
  427. Schilke, J. M., Johnson, G. D., Housh, T. J., et al. (1996). Effects of muscle-strength training on the functional status of patients with osteoarthritis of the knee joint, Nurs. Res. 45, 68–72.PubMedGoogle Scholar
  428. Schnitzer, T. J., Kamin, M., Olson, W. H. (1999a). Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study, Arthritis Rheum. 42, 1370–1377.PubMedGoogle Scholar
  429. Schnitzer, T. J., Truitt, K., Fleischmann, R., et al. (1999b). The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clinical Therapeutics 21, 1688–1702.PubMedGoogle Scholar
  430. Schoen, R. T. and Vender, R. J. (1989). Mechanisms of non-steroidal anti-inflammatory drug-induced gastric damage, Am. J. Med. 86, 449–458.PubMedGoogle Scholar
  431. Schoenfeld, P. (1999). Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials, Am. J. Med. 107(6A), 49S–53S.PubMedGoogle Scholar
  432. Scott, D. L., Berry, H., Capell, H., et al. (2001). The long term effects of non-steroidal anti-infl ammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial, Rheumatology 39, 1095–1101.Google Scholar
  433. Seef, L. B., Cuccherinin, B. A. and Zimmerman, H. J. (1986). Acetaminophen hepatotoxicity in alcoholics, Ann. Int. Med. 104, 399–404.PubMedGoogle Scholar
  434. Seideman, P. and Melander, A. (1988). Equianalgesic effects of paracetamol and indomethacin in rheumatoid arthritis, Br. J. Rheumatol. 27, 117–122.PubMedGoogle Scholar
  435. Sharma, S. C. and Feeley, J. (1996). The influence of aspirin and paracetamol on blood concentrations of alcohol in young adults, Br. Clin. Pharmacol. 41, 467P.Google Scholar
  436. Sheng, H., Shao, J., Washington, M. K., et al. (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells, J. Biol. Chem. 276, 18075–18081.PubMedGoogle Scholar
  437. Siegle, I., Klein, T., Backman, J. T., et al. (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human synovial tissue. Differential evaluation of cyclooxygenase-2 in in-fl ammatory joint diseases, Arthritis Rheum. 41(1), 122–129.PubMedGoogle Scholar
  438. Sigthorsson, G., Tibble, J., Mahmaud, T., et al. (2000). NSAID-induced gastrointestinal damage:the biochemical consequences of the flion trappingflhypothesis, Inflammopharmacology 8, 31–41.Google Scholar
  439. Silas, S. and Clegg, D. O. (1999). Selective COX-2 inhibition, Bull. Rheum. Dis. 48(2), 1–4.Google Scholar
  440. Silverstein, F. E., Graham, D. Y., Senior, J. R., et al. (1995). Misoprostol reduces serious gastrointesti-nal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlledtrial, Ann. Intern. Med. 123, 241–249.PubMedGoogle Scholar
  441. Silverstein, F. E., Faich, G., Goldstein, J. L., et al. (2000). Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritisand rheumatoid arthritis, the CLASS study: A randomised controlled trial. Celecoxib Long-term Arthritis Safety Study, JAMA 284, 1247–1255.PubMedGoogle Scholar
  442. Simkin, P. A. and Bassett, J. E. (1995). Cartilage matrix molecules in serum and synovial fluid, Curr. Opin. Rheumatol. 7, 346–351.PubMedGoogle Scholar
  443. Simmons, D. L., Botting, R. M., Robertson, P. M., et al. (1999). Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroidal-anti-inflammatory drugs, Proc. Natl. Acad. Sci. USA 16, 96 (6), 3275–3280.Google Scholar
  444. Simon, L. S. (1999). Arthritis: new agents herald more effective symptom management, Geriatrics 54, 37–42.PubMedGoogle Scholar
  445. Simon, L. S., Lanza, F. L., Lipsky, P. E., et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor, Arth. Rheum. 41, 1591–1602.Google Scholar
  446. Simon, L. S., Weaver, A. L., Graham, D. Y., et al. (1999). Anti-inflammatory and upper gastrointesti-nal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial, J. Am. Med. Assoc. 282, 1921–1928.Google Scholar
  447. Singh, G. and Ramey, D. R. (1998). NSAID induced gastrointestinal complications: the Aramis perspective, 1997, J. Rheumatol. 25, 8–16.Google Scholar
  448. Situnayake, R. D., Grindulis, K. A. and McConkey, B. (1987). Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods, Ann. Rheum. Dis. 46, 177–183.PubMedGoogle Scholar
  449. Slemenda, C., Brandt, K. D., Heilman, D. K., et al. (1997). Quadriceps weakness and osteoarthritis of the knee, Ann. Intern. Med. 127, 97–104.PubMedGoogle Scholar
  450. Smith, J. B. and Willis, A. L. (1971). Aspirin selectivity inhibits prostaglandin production in human platelet, Chest 59, 12S.PubMedGoogle Scholar
  451. Smith, W. L. and Marnett, L. J. (1991). Prostaglandin endoperoxide synthase: Structure and catalysis, Biochem. Biophys. Acta 1083, 1–17.PubMedGoogle Scholar
  452. Smith, W. L., Garavito, R. M. and Dewitt, D. L. (1996). Prostaglandin endoperoxide H synthases (cyclooxygenase)-1and-2, J. Biol. Chem. 271, 33157–33160.PubMedGoogle Scholar
  453. Solomon, L. (1973). Drug-induced arthropathy and necrosis of the femoral head, J. Bone Joint Surg. 55B, 246.Google Scholar
  454. Somasundaram, S., Hayllar H., Rafi, S., et al. (1995). The biochemical basis of non-steroidal anti-infl ammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis, Scand. J. Gastroenterol. 30, 289–299.PubMedGoogle Scholar
  455. Sorkin, E. M. and Brogden, R. N. (1985). Tiaprofenic acid. A review of its pharmacological efficacy in rheumatic diseases and pain states, Drugs 29, 208–235.PubMedGoogle Scholar
  456. Sowers, M. F. and Lachance, L. (1999). Vitamins and arthritis. The roles of Vitamins A, C, D, and E, Rheum. Dis. Clinic N. Amer. 25, 315–344.Google Scholar
  457. Spaziani, E. P., Lantz, M. E., Benoit, R. R., et al. (1996). The induction of cyclooxygenase-2(COX-2) in intact human amnion tissue by interluekin-4, Prostaglandins 51, 215–223.PubMedGoogle Scholar
  458. Spector, T. D., Hart, D. J. and Nandra, D. (1997). Low level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease, Arthritis Rheum. 40, 723–727.PubMedGoogle Scholar
  459. Steinbrocker, O., Traeger, C. H. and Batterman, R. C. (1949). Therapeutic criteria in rheumatoid arthritis, JAMA 140, 659–662.Google Scholar
  460. Stern, A. I., Hogan, D. L., Kahn, L. H., et al. (1984). Protective effect of acetaminophen against aspirin and ethanol induced damage to the human gastric mucosa, Gastroenterology 86, 728–733.PubMedGoogle Scholar
  461. Stillman, M. T., Napier, J. and Blackshear, J. L. (1984). Adverse effects of nonsteroidal anti-infl ammatory drugs on the kidney, Med. Clin. N. Am. 68, 371–385.PubMedGoogle Scholar
  462. Tannenbaum, H., Davis, P., Russell, A. S., et al. (1996). An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Partici-pants.Google Scholar
  463. Tanojo, H., Wester, R. C., Shainhouse, J. Z., et al. (1999). Diclofenac metabolic profile following in vitro percutaneous absorption through viable human skin, Eur. J. Drug Metab. Pharmacokinet. 24(4), 345–351.PubMedGoogle Scholar
  464. The Cooperating Clinic Committee of the American Rheumatism Association (1965). A seven day variability study of 499 patients with peripheral rheumatoid arthritis, Arth. Rheum. 8, 302–334.Google Scholar
  465. Thecler, R., Sangha, O., Schaeren, S. et al. (1999). Superior responsiveness of the pain and function sections of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). as compared to the Lequesne-Algofunctional Index in patients with osteoarthritis of the lower extremities, Osteoarthritis Cartilage 7, 515–519.PubMedGoogle Scholar
  466. Thomas, M., Michael, M. F., Andrew, P., et al. (1988). A study to investigate the effects of ranitidine on the metabolic disposition of paracetamol in man, Br. J. Clin. Pharmacol. 25, 671.Google Scholar
  467. Thompson, P. W., Kirwan, J. R. and Barnes, G. G. (1985). Practical results of treatment with disease modifying anti-rheumatic drugs, Br. J. Rheumatol. 24, 167–175.PubMedGoogle Scholar
  468. Toda, Y., Toda, T., Takemura, S., et al. (1999). Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritisafter a weight control program, J. Rheumatol. 25, 2181–2186.Google Scholar
  469. Toth, P., Li, X., Lei, Z. M. et al. (1996). Expression of human chorionic gonadotropin (hCG)/ luteinizing hormone receptors and regulation of the cyclooxygenase-1 gene by exogenous hCG in human fetal membranes, J. Clin. Endrocinol. Metab. 81, 1283–1288.Google Scholar
  470. Towheed, T. E. and Anastassiades, T. P. (2000). Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete, J. Amer. Med. Assoc. 283, 1483–1484.Google Scholar
  471. Towheed, T. and Hochberg, M. (1996). Health-relatedquality of life after total hip replacement, Semin. Arthritis Rheum. 26, 483–491.PubMedGoogle Scholar
  472. Towheed, T. E. and Hochberg, M. C. (1997). A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology, Semin. Arthritis Rheum. 26, 755–770.PubMedGoogle Scholar
  473. Trautman, M. S., Edwin, S. S., Collmer, D., et al. (1996). Prostaglandin H synthase-2 in human gestational tissues: Regulation in amnion, Placenta 17, 239–245.PubMedGoogle Scholar
  474. Tréves, R., Maheu, E. and Dreiser, R. L. (1995). Therapeutic trials in digital osteoarthritis. A critical review, Revue du Rhumatologiee English Edition 62 (Suppl.), 33S–41S.Google Scholar
  475. Trials 020, 021, 054, 060, 071, 087. Data on file, G. D. Searle & Co.Google Scholar
  476. Truitt, K., Ettinger, W., Schnitzert, T., et al. (1999). Rofecoxib, a COX-2 specific inhibitor, had clinical efficacy and overall safety in treating osteoarthritis patients aged 80 years and older, Ann. Rheum. Dis. (EULAR), Abstract 859.Google Scholar
  477. Trummlitz, G. and Wittneben, H. (2001). Insight into the structural basis of selective cyclooxygenase-2 inhibition. Abstract, EULAR.Google Scholar
  478. Tsoukas C., Eyster, E., Mukhopadhyay, S., et al. (2001). Efficacy of etoricoxib in the treatment of hemophilic arthropathy, Arthritis Rheum. 44 (Suppl. 9), abstract 429, S124.Google Scholar
  479. Tyson, V. C. H. and Glynne, A. (1980). A comparative study of benoxaprofen and ibuprofen in osteoarthritis general practice, J. Rheum. 7 (Suppl.), 132–138.Google Scholar
  480. Udall, J. A. (1978). Drug interference with warfarin therapy, Clin. Med. 77, 20.Google Scholar
  481. Umbenhauer, E. R. (1983). Diflunisal in the treatment of the pain of osteoarthritis.Summary of clinical studies, Pharmacotherapy 3, 55S–60S.PubMedGoogle Scholar
  482. Vaile J. H. and Davis P. (1998). Topical NSAIDs for musculoskeletal conditions. A review of the literature, Drugs 56, 783–799.PubMedGoogle Scholar
  483. Valentini, M., Cannizzaro, R., Poletti, M., et al. (1995). Nonsteroidal anti-inflammatory drugs for can-cer pain: comparison between misoprostal and ranitidine win prevention of upper gastrointestinal damage, J. Clin. Oncol. 13, 2637–2642.PubMedGoogle Scholar
  484. Valtonen, E. J. (1979a). Symptomatic response of osteoarthritis to benorylate. A dose discrimination study, Scand. J. Rheum. 25 (Suppl.), 9–14.Google Scholar
  485. Valtonen, E. J. (1979b). Clinical comparisonof fenbufen and aspirin in osteoarthritis, Scand. J. Rheum. 27,(Suppl.) 1–7.Google Scholar
  486. van Baar, M. E., Assendelft. W. J., Dekker, J., et al. (1999). Effectiveness of exercise therapy in patients with osteoarthritis of the hip and knee: a systemic review of randomized clinical trials, Arthritis Rheum. 42, 1361–1369.PubMedGoogle Scholar
  487. van Ryn, J., Trummiltz, G. and Pairet, M. (2000). COX-2 selectivity and inflammatory processes, Curr. Med. Chem. 7, 1145–1161.PubMedGoogle Scholar
  488. Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nature 231, 232–235.Google Scholar
  489. Vestal, R. E. (1978). Non-steroidal analgesic and anti-inflammatory agents, Br. Med. J. 287, 39–43.Google Scholar
  490. Vignon, E., Mathieu, P., Broquet, P., et al. (1990). Cartilage degradative enzymes in human osteoarthritis: effect of a nonsteroidal anti-inflammatory drug administered orally, Semin. Arthritis Rheum. 19 (Suppl. 1), 26–29.PubMedGoogle Scholar
  491. Wagner, J. A., Kraft, W., Burke, J., et al. (2001). The COX-2 inhibitor etoricoxib did not alter the anti-platelet effects of low-dose aspirin in healthy volunteers, Arthritis Rheum. 44 (Suppl. 9), abstract 498, S135.Google Scholar
  492. Wagenhauser, F. J. (1973). Long-term study with Brufen, Abstracts of XIII International Congress of Rheumatology, Kyoto, p. 106.Google Scholar
  493. Waldschmidt, J. G., Braunstein, E. M. and Buckwalter, K. A. (1999). Magnetic resonance imaging of osteoarthritis, Rheum. Dis. Clinics North Amer. 25, 451–465.Google Scholar
  494. Wallace, J. L. (1996). NSAID gastroenteropathy: past, present and future, Canad. J. Gastroenterol. 10, 451–459.Google Scholar
  495. Ware, J., et al. (1993). SF-36 manual and interpretation guide. The Health Institute, Boston, Massachusetts.Google Scholar
  496. Warner, T. D., Giuliano, F., Vojnovic, I., et al. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl. Acad. Sci. USA 96, 7563–7568.PubMedGoogle Scholar
  497. Watson, C. P. (1994). Topical capsaicin as an adjuvant analgesic, J. Pain Symptom Management 9, 425–433.Google Scholar
  498. Watson, D. J., Harper, S., Shao, P., et al. (1999). Lower incidence of GI-related discontinuation and 'NSAID-type' symptoms in patients treated with rofecoxib versus non-specific cyclooxygenase inhibitors, Ann. Rheum. Dis. (EULAR) Abstract 863.Google Scholar
  499. Weinberger, M., Tierney, W. M., Booker, P., et al. (1989). Can the provision of information to patients with osteoarthritis improve functional status? A randomized controlled trial, Arthritis Rheum. 32, 1577–1583.PubMedGoogle Scholar
  500. Wessela, J. C., Koelman, H. A., Boneschans, B., et al. (1992). The influence of different types of breakfast on the absorption of paracetamol among members of an ethnic group, Int. J. Clin. Pharmacol. Ther. Toxicol. 30, 208–213.PubMedGoogle Scholar
  501. Whitcomb, D. C. and Block, G. D. (1994). Association of acetaminophen hepatotoxicity with fasting and ethanol use, J. Am. Med. Assoc. 272, 1845–1850.Google Scholar
  502. Wilhelmsen, L., Ljungberg, S., Wedel, H., et al. (1976). Comparison between participants in primary preventative trials, J. Chronic Dis. 29, 331–339.PubMedGoogle Scholar
  503. Williams, H. J., Ward, J. R., Egger, M. J., et al. (1993). Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee, Arthritis Rheum. 36, 1196–1206.PubMedGoogle Scholar
  504. Wilson, J. T., Kasantikul, V., Harbision, R., et al. (1978). Death in an adolescent following an overdose of acetaminophen and phenobarbital, Am. J. Dis. Child. 132, 466–473.PubMedGoogle Scholar
  505. Wojtulewski, J. A., Walter, J. and Gray, J. (1978). Diflunisal compared with naproxen in the treatment of osteoarthritis of hip or knee — a double-blind trial, Curr. Med. Res. Opin. 5, 562–566.PubMedGoogle Scholar
  506. Wolf, M. M. (1996). NSAIDs and the gastrointestinal mucosa, Hospital Practice 31(12), 37–44, 47–48.Google Scholar
  507. Wollheim, F. A. (1999). Serum markers of articular cartilage damage and repair, Rheum. Dis. Clinics North Amer. 25, 417–432.Google Scholar
  508. Yamagata, K., Andreasson, K. I., Kaufman, W. E., et al. (1993). Expression of a mitogen-inducible cyclooxygenase in brain neurons; regulation by synaptic activity and glucocorticoids, Neuron 11, 371–386.PubMedGoogle Scholar
  509. Yang, T., Singh, I., Pham, H., et al. (1997). Regulation of cyclooxygenase expression in the kidney by dietary salt intake, Am. J. Physiol. 274, F481–F489.Google Scholar
  510. Yeomans, N. D., Tulassay, Z., Juhasz, L., et al. (1998). A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs, New Engl. J. Med. 338, 719–726.PubMedGoogle Scholar
  511. Yip, A. S., Chow, W. H., Tai, Y. T., et al. (1990). Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard, Postgrad. Med. J. 66, 367–369.PubMedGoogle Scholar
  512. Yocum, D., Fleischmann, R., Dalgin, P., et al. (2000). Efficacy and safety of meloxicam in the treatment of osteoarthritis, Arch. Int. Med. 160, 2947–2954.Google Scholar
  513. Ytterberg, S. R., Mahowald., M. L. and Woods, S. R. (1998). Codeine and oxycodone use in patients with chronic rheumatic disease pain, Arthritis Rheum. 41, 1603–1612.PubMedGoogle Scholar
  514. Zakar, T., Hirst, J. J., Milovic, J. E., et al. (1995). Glucocorticoids stimulate the expression of prostaglandin endoperoxide H synthase-2 in amnion cells, Endocrinology 136, 1610–1619.PubMedGoogle Scholar
  515. Zhang, W. Y. and LiWanPo, A. (1994). The effectiveness of topically applied capsaicin. A meta-analysis, Eur. J. Clin. Pharmacol. 46, 517–522.PubMedGoogle Scholar
  516. Zimmerman, H. J. and Maddrey, W. C. (1995). Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure, Hepatology 22, 767–773.PubMedGoogle Scholar

Copyright information

© VSP 2002 2002

Authors and Affiliations

  • W. W. Buchanan
  • W. F. Kean

There are no affiliations available

Personalised recommendations